




# UK Standards for Microbiology Investigations

## Investigation of Blood Cultures (for Organisms other than *Mycobacterium* species)



## Acknowledgments

---

UK Standards for Microbiology Investigations (SMIs) are developed under the auspices of Public Health England (PHE) working in partnership with the National Health Service (NHS), Public Health Wales and with the professional organisations whose logos are displayed below and listed on the website <https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories>. SMIs are developed, reviewed and revised by various working groups which are overseen by a steering committee (see <https://www.gov.uk/government/groups/standards-for-microbiology-investigations-steering-committee>).

The contributions of many individuals in clinical, specialist and reference laboratories who have provided information and comments during the development of this document are acknowledged. We are grateful to the Medical Editors for editing the medical content.

We also acknowledge Dr Shabnam Iyer, Dr Mike Weinbren and Ian Sturgess for their considerable specialist input.

For further information please contact us at:

Standards Unit  
Microbiology Services  
Public Health England  
61 Colindale Avenue  
London NW9 5EQ

E-mail: [standards@phe.gov.uk](mailto:standards@phe.gov.uk)

Website: <https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories>

UK Standards for Microbiology Investigations are produced in association with:



Logos correct at time of publishing.

## Contents

---

ACKNOWLEDGMENTS .....	2
AMENDMENT TABLE .....	4
UK SMI: SCOPE AND PURPOSE .....	5
SCOPE OF DOCUMENT .....	7
INTRODUCTION .....	9
TECHNICAL INFORMATION/LIMITATIONS .....	25
1 SAFETY CONSIDERATIONS .....	27
2 SPECIMEN COLLECTION .....	28
3 SPECIMEN TRANSPORT AND STORAGE .....	29
4 SPECIMEN PROCESSING/PROCEDURE .....	29
5 REPORTING PROCEDURE .....	34
6 NOTIFICATION TO PHE OR EQUIVALENT IN THE DEVOLVED ADMINISTRATIONS .....	35
APPENDIX 1: CRITICAL CONTROL POINTS IN BLOOD CULTURE INVESTIGATION .....	36
APPENDIX 2: THERAPEUTIC WINDOW .....	37
APPENDIX 3: INVESTIGATION OF BLOOD CULTURES (FOR ORGANISMS OTHER THAN <i>MYCOBACTERIUM</i> SPECIES) .....	39
REFERENCES .....	40



NICE has accredited the process used by Public Health England to produce Standards for Microbiology Investigations. Accreditation is valid for 5 years from July 2011. More information on accreditation can be viewed at [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

## Amendment Table

Each SMI method has an individual record of amendments. The current amendments are listed on this page. The amendment history is available from [standards@phe.gov.uk](mailto:standards@phe.gov.uk).

New or revised documents should be controlled within the laboratory in accordance with the local quality management system.

Amendment No/Date.	11/04.11.14
Issue no. discarded.	7.1
Insert Issue no.	8
<b>Section(s) involved</b>	<b>Amendment</b>
Whole document.	Hyperlinks updated to gov.uk.
Page 2.	Updated logos added.
Scope.	Sentence on rapid diagnostic tests added. Clarification regarding the release of results following local policy added to Table 3.
Introduction.	Inclusion of sentence regarding the utility of screening surveillance in neonatal units. Addition of text regarding the removal of differential time to positivity and differential quantitative culture from the SMI. Links updated in Rapid Identification section.
Safety Considerations.	Text regarding safety considerations for <i>N. meningitidis</i> added.
Specimen Collection.	Optimal time of specimen collection clarified to include that blood can be sampled at any time.
Culture Media, Conditions and Organisms.	Addition of footnote regarding extended incubation of blood culture bottles for <i>Cryptococcus</i> and <i>Histoplasma</i> species. Addition of cysteine dependent organisms as target organisms of MacConkey/CLED agar.
Reporting Procedure.	Addition of text regarding locally agreed policies for release of results. Clarification of positive microscopy reporting.
References.	References updated.

## UK SMI<sup>#</sup>: Scope and Purpose

---

### Users of SMIs

Primarily, SMIs are intended as a general resource for practising professionals operating in the field of laboratory medicine and infection specialties in the UK. SMIs also provide clinicians with information about the available test repertoire and the standard of laboratory services they should expect for the investigation of infection in their patients, as well as providing information that aids the electronic ordering of appropriate tests. The documents also provide commissioners of healthcare services with the appropriateness and standard of microbiology investigations they should be seeking as part of the clinical and public health care package for their population.

### Background to SMIs

SMIs comprise a collection of recommended algorithms and procedures covering all stages of the investigative process in microbiology from the pre-analytical (clinical syndrome) stage to the analytical (laboratory testing) and post analytical (result interpretation and reporting) stages. Syndromic algorithms are supported by more detailed documents containing advice on the investigation of specific diseases and infections. Guidance notes cover the clinical background, differential diagnosis, and appropriate investigation of particular clinical conditions. Quality guidance notes describe laboratory processes which underpin quality, for example assay validation.

Standardisation of the diagnostic process through the application of SMIs helps to assure the equivalence of investigation strategies in different laboratories across the UK and is essential for public health surveillance, research and development activities.

### Equal Partnership Working

SMIs are developed in equal partnership with PHE, NHS, Royal College of Pathologists and professional societies. The list of participating societies may be found at <https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories>. Inclusion of a logo in an SMI indicates participation of the society in equal partnership and support for the objectives and process of preparing SMIs. Nominees of professional societies are members of the Steering Committee and Working Groups which develop SMIs. The views of nominees cannot be rigorously representative of the members of their nominating organisations nor the corporate views of their organisations. Nominees act as a conduit for two way reporting and dialogue. Representative views are sought through the consultation process. SMIs are developed, reviewed and updated through a wide consultation process.

### Quality Assurance

NICE has accredited the process used by the SMI Working Groups to produce SMIs. The accreditation is applicable to all guidance produced since October 2009. The process for the development of SMIs is certified to ISO 9001:2008. SMIs represent a good standard of practice to which all clinical and public health microbiology

---

<sup>#</sup> Microbiology is used as a generic term to include the two GMC-recognised specialties of Medical Microbiology (which includes Bacteriology, Mycology and Parasitology) and Medical Virology.

laboratories in the UK are expected to work. SMIs are NICE accredited and represent neither minimum standards of practice nor the highest level of complex laboratory investigation possible. In using SMIs, laboratories should take account of local requirements and undertake additional investigations where appropriate. SMIs help laboratories to meet accreditation requirements by promoting high quality practices which are auditable. SMIs also provide a reference point for method development. The performance of SMIs depends on competent staff and appropriate quality reagents and equipment. Laboratories should ensure that all commercial and in-house tests have been validated and shown to be fit for purpose. Laboratories should participate in external quality assessment schemes and undertake relevant internal quality control procedures.

## Patient and Public Involvement

The SMI Working Groups are committed to patient and public involvement in the development of SMIs. By involving the public, health professionals, scientists and voluntary organisations the resulting SMI will be robust and meet the needs of the user. An opportunity is given to members of the public to contribute to consultations through our open access website.

## Information Governance and Equality

PHE is a Caldicott compliant organisation. It seeks to take every possible precaution to prevent unauthorised disclosure of patient details and to ensure that patient-related records are kept under secure conditions. The development of SMIs are subject to PHE Equality objectives <https://www.gov.uk/government/organisations/public-health-england/about/equality-and-diversity>.

The SMI Working Groups are committed to achieving the equality objectives by effective consultation with members of the public, partners, stakeholders and specialist interest groups.

## Legal Statement

Whilst every care has been taken in the preparation of SMIs, PHE and any supporting organisation, shall, to the greatest extent possible under any applicable law, exclude liability for all losses, costs, claims, damages or expenses arising out of or connected with the use of an SMI or any information contained therein. If alterations are made to an SMI, it must be made clear where and by whom such changes have been made.

The evidence base and microbial taxonomy for the SMI is as complete as possible at the time of issue. Any omissions and new material will be considered at the next review. These standards can only be superseded by revisions of the standard, legislative action, or by NICE accredited guidance.

SMIs are Crown copyright which should be acknowledged where appropriate.

## Suggested Citation for this Document

Public Health England. (2014). Investigation of Blood Cultures (for Organisms other than *Mycobacterium* species). UK Standards for Microbiology Investigations. B 37 Issue 8. <https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories>

## Scope of Document

---

### Type of Specimen

Blood

Other specimens may be processed in blood culture bottles where appropriate (see [B 26 – Investigation of Fluids from Normally Sterile Sites](#) and [B 38 – Investigation of Bone Marrow](#)).

### Scope

This method describes the processing and microbiological investigation of blood cultures and aims to set standards for each stage of the investigative process. Rapid diagnostic tests on positive blood cultures are available, and should be considered for use following validation. Direct molecular techniques on clinical specimens are not covered in this SMI. The SMI does not address the detection of parasites, viruses (see [V 10 - Blood Borne Virus Testing in Dialysis Patients](#)), or *Mycobacterium* species (see [B 40 – Investigation of Specimens for \*Mycobacterium\* species](#)) and does not list specific details of commercially available systems.

This SMI should be used in conjunction with other SMIs.

### Standards

To optimise the clinical utility of blood culture results, the interval between collection of samples and reporting of results should be kept to a minimum. The recommended turnaround time (TAT) from collection to reporting is between one and five days (longer if fungal infection is suspected, if extended incubation is required, or if isolates are sent to a reference laboratory for confirmation)<sup>1</sup>. By breaking down the blood culture process, it is possible to identify critical control points where there may be delays or the potential to improve TATs (Appendix 1) leading to improved patient outcomes (Appendix 2)<sup>2</sup>. The process can be subdivided into pre-analytical, analytical and post-analytical phases, all of which should be completed within the recommended time frame.

Once implemented, standards should be audited regularly to ensure that they are met and to evaluate current service provision<sup>3</sup>. These standards are designed to emphasise the critical nature of the blood culture specimen for patient management; they do not assume that the pathology service is required to invest in specific equipment, but encourage the optimal use of the resources already in place.

#### Summary Table 1: Pre-Analytical Standards<sup>1,2,4-6</sup>

Inoculated bottles should be incubated as soon as possible, and within a maximum of four hours.

Investigative Stage:	Standard:
Pre-Analytical	Time Period
Collection to Incubation	≤4hr

The four hour TAT from collection to incubation for blood culture samples reflects their clinical significance.

**Summary Table 2: Analytical Standards<sup>7-11</sup>**

Results of the following identification and sensitivity tests (if performed) should be completed within the following time frames from flagging positive:

Investigative Stage:	Criteria:	Standard:
<b>Analytical</b>		
Flagging Positive to Microscopy, Identification and Sensitivities	<b>Test</b> (if test performed)	<b>Time Period to Result</b>
	Gram Stain	≤2hr
	Rapid Antigen Testing	≤2hr
	Molecular Assays	same day
	Isolate Identification (Direct/Automated)	≤24hr
	Isolate Identification (Conventional Methods)	24-48hr
	Isolate Sensitivities (Direct/Automated)	≤24hr
	Isolate Sensitivities (Conventional Methods)	24-48hr

**Summary Table 3: Post-Analytical Standards<sup>12-19</sup>**

Standards have also been set for the laboratory TAT (the time between receipt in the laboratory and reporting):

Investigative Stage:	Criteria:	Standard:
<b>Post-Analytical</b>		
Negative Report (from receipt in laboratory to negative reporting)	<b>Report Type</b>	<b>Turnaround time</b>
	Preliminary Negative Report	48hr * (dependant on local policy)
	Final Negative Report	≤5 days (or greater if extended incubation required)
Positive Report (from receipt in laboratory to positive reporting)	Preliminary Positive Report (Release results following local policy: Telephone/Fax/Email/Electronic)	Immediately, within 2hr of identity/sensitivity availability. (see Summary Table 2 above)
	Final Positive Report	≤5 days (or greater if extended incubation required, or if isolates are sent to a reference laboratory for confirmation)



\*Refer to neonatal sepsis section of the introduction for further information regarding negative reporting of neonatal blood culture<sup>18,20</sup>.

## Introduction

---

Blood culture is considered to be the “gold standard” investigation for the detection of micro-organisms in blood<sup>21</sup>. The culture of micro-organisms from blood is essential for microbiological diagnosis of bacteraemia, fungaemia, infective endocarditis and conditions associated with a clinical presentation of pyrexia of unknown origin (PUO)<sup>21,22</sup>. Blood culture is also important for the diagnosis of prosthetic device infections (eg joints and vascular grafts) and intravascular line-associated sepsis. Blood cultures may also detect bloodstream infections associated with other conditions such as pneumonia, septic arthritis and osteomyelitis.

Antibiotic resistance amongst pathogens (particularly Gram negative bacteria) is the most frequent cause of ineffective empirical treatment in bloodstream infection. Early identification and antibiotic susceptibility results for blood culture isolates provide valuable diagnostic information on which appropriate antimicrobial therapy can be based, so helping to reduce morbidity and mortality, improve patient care and reduce healthcare costs<sup>23-26</sup>. Decreasing turnaround times (TAT) at each stage of the process from transportation of samples to reporting of results is therefore recommended<sup>21</sup>.

## Bloodstream Infection

The bloodstream contains many antimicrobial components including lysozyme, leucocytes, immunoglobulin and complement. Organisms may enter the bloodstream from a focus of infection within the body, a surface site colonised with normal flora through broken skin or mucous membrane, the gastrointestinal tract or by the direct introduction of contaminated material to the vascular system<sup>23</sup>. These bacteria are normally removed from the bloodstream within a few minutes; only when the host defences are overwhelmed or evaded does systemic infection become apparent. Mortality is related to the type of infecting organism and the nature of any underlying disease<sup>27,28</sup>. Blood stream infection is caused by bacteria (bacteraemia) or fungi (fungaemia) in the blood and may be transient, intermittent or continuous<sup>12</sup>.

### Transient

The transient presence of bacteria or fungi in the bloodstream for periods of several minutes may follow manipulation of, or surgical procedures involving infected tissue or the instrumentation of colonised mucosal surfaces. Common examples include dental extraction and urinary catheterisation. It may also result from chewing especially if dental hygiene is poor. Defaecation may also be associated with small numbers of bacteria entering the bloodstream. Pressure on boils or minor skin conditions (eg squeezing spots) can lead to transient bacteraemia. Intravenous drug use may also be a source through contaminated needles or drugs. Transient bacteraemia also occurs in association with localised infections such as pneumococcal pneumonia and pyelonephritis.

### Intermittent

Intermittent infection is "recurrent transient" infection and is characteristically associated with undrained, intra-abdominal abscesses. It occurs early in the course of a variety of systemic and localised infections, eg pneumococcal bacteraemia in pneumococcal pneumonia. Cultures taken during fevers and after the onset of rigors

may miss intermittent bacteraemia as bacteria tend to be cleared by the host defence mechanisms prior to sampling.

## Continuous

Continuous bacteraemia suggests a severe infection that has overwhelmed the host defence. It is also characteristic of intravascular infection such as infective endocarditis or suppurative thrombophlebitis. Occasionally, continuous bacteraemia occurs in association with non-vascular sources, especially in patients who are immunosuppressed.

## Pseudobacteraemia

Pseudobacteraemia occurs when blood culture isolates originate from outside the patient's bloodstream. Blood culture contamination may occur at any stage between taking a blood sample and processing in the laboratory, and can originate from a variety of sources. Outbreaks of pseudobacteraemia with environmental organisms have been described involving contaminated fluids and equipment on wards and laboratories, and incorrect sampling of blood<sup>29,30</sup>.

## Sepsis<sup>31-33</sup>

The term Systemic Inflammatory Response Syndrome (SIRS) describes the early response of the body to injury and may be infective or non-infective in origin<sup>34</sup>. SIRS is present when two or more of the following clinical features are present<sup>34</sup>:

- Body temperature  $<36^{\circ}\text{C}$  or  $>38^{\circ}\text{C}$
- Heart rate  $>90$  beats per minute
- Hyperventilation  $>20$  breaths per minute
- White blood cell count  $>12,000$  cells per  $\mu\text{L}$  or  $<4000$  cells per  $\mu\text{L}$

Sepsis was previously referred to as septicaemia. Sepsis is the presence of SIRS caused by infection. It is defined as infection plus a systemic response to, or manifestation of, infection<sup>31,34</sup>. Around 20% of sepsis cases are associated with bacteraemia, the rest are secondary to infection at other sites in the body<sup>34</sup>. The incidence of sepsis continues to rise with a reported associated mortality rate of 35 - 65%<sup>35</sup>. Early and appropriate empirical antibiotic treatment is associated with decreased mortality rates and improved clinical outcomes<sup>24,35</sup>. In severe sepsis each hour of delay in antibiotic treatment results in increased mortality<sup>25,36</sup>.

In the immunocompromised host, sepsis is defined as SIRS with one or more of the clinical features present, combined with an infective aetiology.

## Severe Sepsis

Severe sepsis is defined as sepsis plus sepsis-induced organ dysfunction or tissue hypoperfusion<sup>31</sup>.

## Septic Shock

Septic shock is defined as the persistence of sepsis-induced hypotension despite adequate fluid resuscitation<sup>31</sup>. The clinical symptoms are usually attributed to toxic bacterial products and/or the host response to these. Shock is more commonly seen with Gram negative septicaemia, but shock may also be associated with Gram

positive organisms, particularly with fulminant pneumococcal, Lancefield Group A streptococcal and staphylococcal bacteraemia<sup>33</sup>.

Intravenous antibiotic therapy within the first hour of recognition of septic shock and severe sepsis is recommended as antimicrobial agents are of little help in combating the acute effects of shock<sup>31</sup>. Other supportive measures, such as fluid therapy, mechanical ventilation and the maintenance of blood pressure, are essential.

## Neonatal Sepsis<sup>37,38</sup>

Neonatal sepsis is defined as clinically diagnosed SIRS caused by infection occurring within the first four weeks of life. The incidence of neonatal sepsis increases with low birth weight or prematurity and can be divided into two types:

### Early onset neonatal sepsis<sup>18,37</sup>

Early onset neonatal sepsis occurs in the first 72 hours of life and is usually caused by infection ascending from the maternal genital tract or, less commonly, via the placenta.

### Late onset neonatal sepsis<sup>37</sup>

Late onset neonatal sepsis occurs after the first 72 hours of life and the organisms may be acquired from the external environment (eg hospital or home). Infection is often transmitted via the hands of care providers; organisms initially colonise superficial sites and the upper respiratory tract and progress to cause widespread sepsis, pneumonia or meningitis.

Organisms isolated from superficial sites, gastric aspirate and amniotic fluid indicate colonisation, and may include pathogens responsible for neonatal sepsis. However, they do not establish the presence of active systemic infection. Isolation of organisms from blood remains the gold standard for diagnosing systemic bacterial infection in neonates. Organisms associated with neonatal sepsis include<sup>37,38</sup>:

- $\beta$ -haemolytic streptococci, in particular Lancefield group B streptococci
- *Enterobacteriaceae*
- *S. aureus*
- Coagulase negative staphylococci
- *Listeria monocytogenes*
- *Enterococcus* species
- Pseudomonads
- Yeasts

Neonatal sepsis caused by anaerobic bacteria has been reported; the majority of cases being due to *Bacteroides* species, *Clostridium* species or *Peptostreptococcus* species<sup>39</sup>.

The utility of surveillance screening has been debated<sup>40</sup>. Surveillance screening is performed routinely in many neonatal units and may be used to monitor trends in resistant flora and define antibiotic policies<sup>41</sup>.

Following NICE guidance on antibiotic use in early onset neonatal infection, negative blood culture results, at 36hr after collection, may be used as a basis for

discontinuation of antibiotic treatment. It has been suggested that 36hr incubation is sufficient to rule out sepsis in asymptomatic neonates: however, blood cultures collected from neonates < 72hr old may require longer incubation<sup>18,20,42</sup>.

## Bloodstream Infections in Patients who are Immunocompetent

### Community acquired

Community acquired bacteraemia and fungaemia often arises in previously healthy individuals, usually in association with demonstrable focal infection such as pneumococcal pneumonia. Bacteria may also enter the blood from the patient's own commensal flora or from an undetected infected site and cause metastatic infection (as is sometimes the case in *Staphylococcus aureus* osteomyelitis). Other generalised bacteraemic illnesses include enteric fever (eg typhoid) and brucellosis.

Organisms most commonly isolated from adults with community acquired bacteraemia include:

- *Escherichia coli*
- *Streptococcus pneumoniae*
- *S. aureus*
- Other *Enterobacteriaceae*
- *Neisseria meningitidis*
- $\beta$ -haemolytic streptococci

### Hospital acquired

The increasing number of invasive procedures such as catheterisation, immunosuppressive therapy, antibiotic therapy, and life support measures has resulted in an overall increase in hospital acquired bacteraemia, candidaemia and other fungaemia. These procedures may introduce organisms to the bloodstream or may weaken host defences. Organisms most frequently isolated from adults with hospital acquired bloodstream infection will depend on the patient group, and may change with the duration of stay in hospital. Organisms include<sup>43</sup>:

- Coagulase negative staphylococci
- *E. coli*
- *S. aureus*
- Other *Enterobacteriaceae*
- *Pseudomonas aeruginosa*
- Enterococci
- Anaerobes
- *S. pneumoniae*
- Yeasts

Many other organisms have been implicated in both hospital and community-acquired bacteraemia<sup>44-52</sup>.

## Healthcare associated infection (HCAI)

HCAI are infections that occur as a result of healthcare interventions including care or treatment provided in the home, at the doctor's surgery or clinic, in nursing homes or following care given in a hospital. It is often difficult in patients who receive regular care to determine with accuracy whether infection is community or healthcare associated; co-operation between Public Health and Infection Control teams is therefore essential for investigative and epidemiological purposes.

## Anaerobic bacteraemia

Studies have shown that anaerobic organisms account for between one and seventeen percent of positive blood cultures; anaerobic organisms are therefore an important cause of bacteraemia and should be tested for routinely<sup>39,53-55</sup>. Organisms most commonly associated with anaerobic bacteraemia include<sup>39</sup>:

- Gram negative bacilli, including *Bacteroides* and *Fusobacterium* species
- Peptostreptococcus
- *Clostridium* species

## Bloodstream infection in children

The aetiology of paediatric bacteraemia has changed in recent years. Infections with *Haemophilus influenzae* type b have declined dramatically following the introduction of the Hib immunisation programme, and systemic nosocomial infections have increased. Organisms most commonly isolated from children with community acquired bacteraemia include:

- *S. pneumoniae*
- *N. meningitidis*
- *S. aureus*
- *E. coli*

Organisms implicated in nosocomial infections in children are similar to those seen in adults; polymicrobial and anaerobic bacteraemia, however, occur less frequently<sup>56</sup>.

Occult bacteraemia can occur in children with few or none of the symptoms normally associated with bloodstream infection<sup>57</sup>. Pyrexia may be the only indicator, and is non-specific. *S. pneumoniae* predominates, but occult infection with *H. influenzae*, *Salmonella* species and *N. meningitidis* has also been described.

## Catheter-related bacteraemia

Confirmation that the catheter is the source of infection in intravenous catheter (IVC) related bacteraemia or fungaemia is often difficult. There is often no evidence of infection at the catheter insertion site, and the organisms involved are frequently part of the normal skin flora and are common contaminants of blood cultures.

Diagnosis of catheter related bacteraemia is usually based on<sup>58,59</sup>:

- isolation of the same organism from the blood and purulent IVC insertion site or IVC tip
- clinical sepsis, unresponsive to antimicrobial therapy, that resolves on catheter removal

Differential time to positivity, and differential quantitative culture (as a means of diagnosing catheter related bacteraemia) have been removed from this SMI due to doubts regarding the reliability of these methods. The methods are based on the assumption that if a catheter is the source of infection, blood drawn through it will have a higher bacterial load, and therefore a shorter time to positivity compared to peripheral blood<sup>60-62</sup>. Results of studies have been variable, with some studies reporting statistically significant differences in bacterial load and time to positivity, and others reporting no significant difference<sup>63-65</sup>. With the advancement of technology used in continuous monitoring blood culture systems, it is likely that sensitivity of detection will improve, making the use of quantitative differential time to positivity questionable<sup>59</sup>. In addition to this, differential time to positivity cannot be applied in cases of polymicrobial infection<sup>60</sup>.

## Pregnant women

*Listeria monocytogenes* may cause serious infection in pregnant women. Sepsis caused by *L. monocytogenes* presents as an acute febrile illness that may affect the fetus<sup>66,67</sup>. This may lead to systemic infection (granulomatosis infantisepticum), stillbirth or neonatal meningitis. Products of conception, placenta and neonatal screening swabs should be examined for this organism. Routine culture of vaginal swabs for *L. monocytogenes* is not usually performed but may be useful in suspected cases<sup>66</sup>.

Septic abortion may result in serious maternal morbidity and may be fatal. Uterine perforation, presence of necrotic debris and retained placental products can all lead to infection; most infections are polymicrobial and involve anaerobes. Clostridial sepsis complicating abortion is potentially lethal. *Clostridium* species are part of the normal vaginal flora in some women.

## Infective endocarditis (IE)<sup>68</sup>

IE is defined as an infection of the heart valves and/or other areas of the endocardium. It usually occurs at the site of a predisposing cardiac lesion or congenital defect where there is turbulent blood flow, encouraging endocardial damage and adhesion of platelets<sup>69-71</sup>. A fibrin clot is deposited on the damaged endocardial surface and becomes colonised with organisms which have entered the bloodstream, so forming infected vegetations. Viable bacteria may be present deep within, as well as on the surface of the vegetation making antimicrobial treatment difficult<sup>72</sup>.

Historically, the disease was classified as either "acute" or "subacute", relating to the usual course of the untreated disease. Proposed in 1994, the Duke criteria are now used for diagnosis<sup>69</sup>. It is more usual to describe the disease in relation to the infecting organism or the underlying anatomy.

### Native valve endocarditis

Chronic rheumatic heart disease (RHD) was the main predisposing factor in IE, but has now been replaced by other conditions such as congenital heart disease, mitral valve prolapse, and degenerative valvular disease in the elderly. Infective endocarditis can occur on anatomically and functionally normal valves as a result of certain bacteraemias. Organisms most commonly isolated include<sup>72</sup>:

- oral streptococci
- Staphylococci (approximately 80% of these are *S. aureus*)

## Investigation of Blood Cultures (for Organisms other than *Mycobacterium* species)

- Enterococci
- *Streptococcus bovis* (*S. bovis* biotype 1 may also be referred to as *S. gallolyticus subsp. gallolyticus*)<sup>73</sup>

Fungal infection is rare, except in intravenous drug users and patients with severe underlying illnesses, and requires immediate treatment or surgery<sup>74,75</sup>. Many other organisms have been described, including some that are fastidious, and that rarely cause human disease other than endocarditis (eg the HACEK group: *Haemophilus* species, *Aggregatibacter* species, *Cardiobacterium* species, *Eikenella corrodens* and *Kingella* species (see [ID 12 - Identification of \*Haemophilus\* species and the HACEK Group of Organisms](#))<sup>69,76</sup>. The utility of extended blood culture incubation for these organisms has been investigated; several studies have shown that extended incubation is unnecessary when using continuous monitoring blood culture systems<sup>76-78</sup>. *Bartonella* species are becoming increasingly important causes of endocarditis particularly in patients with HIV infection<sup>71</sup>.

### Prosthetic valve endocarditis (PVE)

In addition to antimicrobial therapy, infected valves frequently require surgical removal and replacement either to eradicate infection or because of leakage problems. Infection may occur at any time after valve surgery, but becomes progressively less common as time passes and involves a different group of organisms. The risk of PVE in the first year is 1-5%, and after one year this decreases to about 1%<sup>72</sup>. The prosthetic aortic valve is more prone to infection.

“Early” PVE usually occurs within 60 days of implantation, but illness characteristic of early disease may not become apparent until 4-6 months after valve replacement. These infections reflect contamination of the valve prosthesis in the peri-operative period. Contamination usually occurs intra-operatively. “Early” PVE has a higher mortality rate than “late” PVE, and the causative organisms are often more resistant to antibiotics, probably reflecting their hospital origin and the use of prophylactic and therapeutic antibiotics peri-operatively.

The most commonly isolated organisms are<sup>72</sup>:

- coagulase negative staphylococci
- *S. aureus*
- Gram negative rods
- *Candida* species
- Streptococci and enterococci
- *Corynebacterium* species

“Late” PVE may occur several years after valve implantation. The source of the infection is thought to be a transient bacteraemia or fungaemia seeding the valve as occurs in the infection of native valves, although it may be a result of delayed presentation of a hospital-acquired infection. The organisms responsible are similar to those implicated in native valve endocarditis and include:

- oral streptococci
- Staphylococci
- Gram negative rods

- *Candida* species
- Enterococci
- *Corynebacterium* species

### Bloodstream Infection in Patients who are Immunocompromised

Patients who are immunocompromised include those with inherited, acquired or drug-induced abnormalities of the immune system. Defects in phagocytes, complement, antibody formation and cell-mediated immunity are often associated with a particular disorder or disease such as malignancy, HIV infection or sickle cell disease, and in patients who have had organ transplantation, immunosuppressive therapy or steroids<sup>79</sup>. The risk of infection is greatest in patients with neutropenia in whom Gram negative bacteria cause severe sepsis associated with a high mortality rate<sup>80</sup>.

In patients who are immunocompromised, there is a high incidence of infection caused by organisms that are non-virulent in the normal host and that form part of the normal host flora. These would usually be considered as contaminants in the immunocompetent host<sup>80</sup>. Examples are coagulase negative staphylococci, enterococci and viridans streptococci.

Hyposplenic or asplenic patients are susceptible to fulminating sepsis caused by a variety of organisms, particularly capsulate bacteria such as *S. pneumoniae*, *H. influenzae* and *N. meningitidis*, but also less common organisms such as *Capnocytophaga* species<sup>52,81</sup>.

The spectrum of organisms detected reflects lengthening periods of neutropenia and duration of hospital stay, and an increased use of indwelling central venous catheters (CVC) and of broad-spectrum antibiotics. Polymicrobial infections are more common in this group of patients and the number of Gram positive and opportunistic infections, particularly those caused by fungi and *Mycobacterium* species, has also increased<sup>52</sup>. In addition to the organisms associated with bloodstream infection in the immunocompetent, isolates include<sup>81</sup>:

- non-fermentative Gram negative rods
- *Listeria monocytogenes*
- *Corynebacterium* species
- *Candida* species

Other unusual organisms including a variety of bacteria and fungi may be isolated, many of which have very specific growth requirements<sup>81-83</sup>.

### Post Mortem Blood Cultures

Post mortem blood cultures have been shown to be associated with significantly higher positive rates than blood cultures sampled during life. However, providing bodies are kept under controlled refrigerated conditions and post mortem examination occurs within 2-10 days, it has been shown that there is no further increase in positive culture rates<sup>84,85</sup>. Results of post mortem blood cultures and their clinical significance should be interpreted with caution; however, they may be useful in the investigation of sudden unexpected death in infants and children (SUDI)<sup>84-87</sup>.



## Unusual Organisms Likely to be Involved in a Deliberate or Accidental Release of Infection (Bioterrorism or Biological Warfare)

In the absence of any other risk factor (eg foreign travel, clinical laboratory or veterinary work posing an infection hazard) cases or clusters of the organisms below could suggest the possibility of a deliberate or accidental release of micro-organisms. Such events require a rapid response; suspicion of deliberate or accidental release of micro-organisms must be notified urgently to the Public Health England 24hr Duty Doctor at Microbiology Services Colindale. The following list of organisms is not all inclusive; the organisms are reportable to PHE under the HPA (Notification) Regulation 2010; a comprehensive list of causative agents notifiable to the PHE is available at: <https://www.gov.uk/notifiable-diseases-and-causative-organisms-how-to-report>.

Other arrangements exist in [Scotland](#)<sup>88,89</sup>, [Wales](#)<sup>90</sup> and [Northern Ireland](#)<sup>91</sup>.

If the following organisms are suspected, investigation should be carried out at containment level 3 unless otherwise stated. Suspect isolates should be sent to the appropriate reference laboratory for characterisation:

- *Bacillus anthracis* (Anthrax)
- *Brucella* species (Brucella)
- *Francisella tularensis* (Tularemia)
- *Burkholderia mallei* (Glanders)
- *Burkholderia pseudomallei* (Meliodiosis)
- *Clostridium botulinum* (Botulism) may be investigated at Containment level 2 in a Microbiological Safety Cabinet

Refer to [ID 8 - Identification of \*Clostridium\* species](#)

- *Coxiella burnetii* (Q fever)
- *Yersinia pestis* (Plague)

**Note:** *Brucella* species, *B. mallei*, *B. pseudomallei* and *Y. pestis* are listed in the databases of a number of commercially available kit-based identification systems; results should however be interpreted with caution.

**Note:** *B. anthracis*, *Brucella* species, *C. botulinum* and *Y. pestis* all cause disease which is reportable to the Local Authority Proper Officer under the Health Protection (Notification) Regulations 2010. A comprehensive list of diseases notifiable to the Local Authority Proper Office under the Health Protection (Notification) Regulations 2010 is available at:

<https://www.gov.uk/notifiable-diseases-and-causative-organisms-how-to-report>

**Note:** Brucellosis is reportable under the Zoonosis Order 1989.

## Increasing Antibiotic Resistance<sup>92-94</sup>

Antibiotic resistance, especially amongst Gram negative bacteria, has increased markedly<sup>87</sup>. Previously, Gram negative bacteria were, in general, sensitive to aminoglycosides, third generation cephalosporins and fluoroquinolones. However, resistance mechanisms have evolved to not just one, but several classes of antibiotics simultaneously<sup>87</sup>. Of concern are extended spectrum  $\beta$ -lactamase producing (ESBL)

Enterobacteriaceae, carbapenemase producing *Enterobacteriaceae* and multidrug resistant *Pseudomonas aeruginosa*<sup>92,95</sup>. The incidence of multidrug resistance in Gram positive organisms such as *S. aureus*, coagulase negative staphylococci and enterococci has also increased in recent years<sup>92</sup>. The net result is an increasing number of patients for whom initial empirical antibiotic therapy is ineffective<sup>24</sup>.

The prevalence of multi drug resistant Gram negative bacteria, meticillin resistant *S. aureus* (MRSA), vancomycin-resistant enterococci (VRE) and other resistant organisms highlights the need for accurate and timely blood culture results to ensure correct antibiotic treatment is being administered and to reduce the overall use of broad spectrum antibiotics<sup>25,26,92,96</sup>.

## Blood Culture Systems

The ideal blood culture system produces the maximum yield of pathogen in as short a time as possible in order to have the greatest influence on patient management, thereby generating the best outcomes.

The introduction of commercial, fully automated, continuous-monitoring blood culture systems has led to earlier detection and better identification of pathogens. This is particularly true of organisms considered most pathogenic, for example *S. aureus*, Gram negative rods and streptococci<sup>12</sup>. However, blood culture does have its limitations.

### Pre-analytical<sup>6</sup>

The pre-analytical stage from collection to loading is dependent on many factors:

- the location of the laboratory in relation to the ward (onsite/offsite)
  - external transportation arrangements (frequency, out of hours service)
  - internal transfer arrangements (frequency, availability of pneumatic tube transport, out of hours service)
- level of laboratory out of hours service provision (out of hours loading frequency)
- equipment available and developments in current technology (availability of continuous monitoring blood culture system, pre incubation incubator)

Blood cultures should ideally be placed on the continuous monitoring blood culture machine 24 hours a day, as soon as possible after collection and within a maximum of 4hr.

Traditionally, where direct placement on a machine is not possible, blood cultures have been pre-incubated in a separate incubator. An inadvertent consequence of this is that a percentage of positive cultures may not be detected once placed on the blood culture machine after pre incubation (see Technical Information/Limitations).

Consequently many laboratories do not now pre-incubate blood cultures leaving them at room temperature overnight, leading to an increased time to detection (time from loading to flagging positive) once placed on the machine (see Technical Information/Limitations/Appendix 1). A balance between obtaining false negative blood culture and incurring significant delays in the Gram stain result must be carefully considered.

A decrease in the time to positivity (time from collection to flagging positive) can be achieved in a number of ways depending on local facilities and resources<sup>6</sup>:

## Investigation of Blood Cultures (for Organisms other than *Mycobacterium* species)

- consider external and internal transport arrangements to decrease collection to loading time
- consider shift working patterns or out of hours laboratory cover to decrease collection to loading time
- consider use of non-Microbiology (eg Blood Sciences) personnel to load machines out of hours
- consider the use of equipment. For example the time of operation of pre-incubators can be controlled using a seven day programmable time switch. Blood cultures received outside of normal working hours would be loaded in the incubator overnight and powered for a limited number of hours (eg midnight to 9am). This would decrease time to positivity.
- consider new developments/advances in current technology which decrease the collection to loading time and time to positivity

### Analytical

The time to detection (TTD) once samples are loaded is dependent on the time required for multiplication to a significant level to occur; fastidious or non-cultureable organisms may fail to grow and sensitivity may be decreased when samples are taken directly after antibiotic treatment<sup>2</sup>.

Blood culture systems should therefore aim to achieve the following:

- a culture medium as rich as possible to allow the recovery of very small numbers of a variety of fastidious organisms
- neutralisation or removal of antimicrobial substances, either natural blood components or antimicrobial agents
- minimisation of contamination
- earliest possible detection of bacteria and fungi

Blood culture systems rely on a variety of detection principles and cultural environments to detect micro-organisms. Many systems and their respective media have been compared; each system having its own limitations and advantages<sup>12,78,97-101</sup>. Fully automated continuous monitoring systems are simple to use in comparison with manual and semi-automated systems.

Most systems employ both aerobic and anaerobic bottles for adults, but provide a single aerobic bottle for use with children for whom blood specimen volumes obtained are often small<sup>102</sup>.

### Factors Affecting Isolation of Causative Organisms

A number of clinical and technical factors may affect the isolation of the infecting organism, regardless of the system employed<sup>12,52</sup>.

#### Clinical:

##### Method of collection

Collection of blood from the patient should be carried out following Department of Health guidance<sup>103</sup>.

Studies have shown that discarding the first 10mL aliquot of blood taken from vascular catheters has no effect on the contamination rate of these samples and that, even following strict sterile precautions; samples taken from central venous catheters have higher contamination rates than those taken from peripheral or arterial lines<sup>104,105</sup>. Arterial blood offers no advantage over venous blood for detection of most micro-organisms, although it has been reported as being superior in detecting disseminated fungal disease<sup>106</sup>. Changing needles between venepuncture and inoculation of the bottles is not recommended because this carries a risk of needle stick injury. Needle changing does not reduce contamination rates according to some authorities, but slightly reduces contamination according to a meta-analysis<sup>30,59,107-109</sup>.

### **Number and timing of samples**

For the majority of patients, two blood culture sets are recommended. A second or third set taken from a different site not only increases yield but also allows recognition of contamination<sup>110</sup>. In most conditions other than endocarditis, bacteraemia is intermittent, given it is related to the fevers and rigors which occur 30-60 minutes after the entry of organisms into the bloodstream. Samples should be taken as soon as possible after a spike of fever. However, one study has shown no significant difference in isolation rates for blood drawn either at intervals or taken simultaneously with fever spikes<sup>111</sup>. Certainly, the timing is less important for continuous bacteraemia, as seen in infective endocarditis.

### **Previous antimicrobial therapy<sup>2</sup>**

Ideally, blood samples should be taken prior to antimicrobial treatment. When already receiving antimicrobials, blood culture should be collected just before the next dose is due when antimicrobial concentration in the blood is at the lowest. Any recent antimicrobial therapy can have a significant effect on blood culture results by decreasing the sensitivity of the test. This may be of particular importance in those patients receiving prophylactic antibiotics and who are at high risk of bloodstream infections. If patients have received previous antimicrobial treatment, bacteraemia should be considered even if blood culture results are negative.

### **Volume of blood**

Blood culture volume is the most significant factor affecting the detection of organisms in bloodstream infection. There is a direct relationship between blood volume and yield, with approximately a 3% increase in yield per mL of blood cultured. False negatives may occur if inadequate blood culture volumes are submitted<sup>112</sup>.

The number of organisms present in adult bacteraemia is frequently low, often  $<1 \times 10^3$  colony forming units per litre (cfu/L)<sup>113</sup>. For adult patients it is recommended that 20-30mL of blood be cultured per set<sup>54,114</sup>. Most modern commercial systems allow 10mL blood to be added to each bottle. Manufacturers' optimum blood volume recommendations vary; manufacturers' instructions should be read prior to use.

Data regarding the optimum total blood volume per set for neonates and children is limited. The criteria for calculating total blood culture volumes is often based on weight rather than age and relates to total patient blood volume<sup>112</sup>. In infants and children the magnitude of bacteraemia is usually higher than that in adults; therefore, sensitivity of detection is not significantly reduced by lower blood-to-medium ratio. It has been suggested that the volume of blood drawn should be no more than 1% of the patient's total blood volume<sup>115,116</sup>.

Low level bacteraemia ( $<4 \times 10^3$  cfu/L) in neonates and children does occur with clinically significant organisms. One study suggests that for the reliable detection of low level bacteraemia, 4 - 4.5% of a patient's total blood volume, not 1%, should be cultured<sup>117</sup>.

## Technical:

### Media used

Most systems employ different media for the isolation of aerobic and anaerobic organisms. Some media are specifically designed for the detection of organisms such as fungi and *Mycobacterium* species. A variety of blood culture media and systems have been evaluated and are commercially available<sup>97,118-121</sup>. Media differ in the type and proportion of various supplements and anticoagulants, volume of broth, headspace atmosphere and the presence of antimicrobial-neutralising agents. Aerobic bottles now rarely require venting when using fully automated continuous monitoring systems<sup>122,123</sup>. Aerobic bottles using other systems may require transient venting to increase the oxygen content in the headspace for strictly aerobic organisms such as *P. aeruginosa* and *Candida albicans*<sup>12,124-126</sup>.

A blood to broth ratio of about 1:15 is required to remove the antibacterial effects of normal human blood, this may be reduced to between 1:5 and 1:10 by the addition of 0.05% sodium polyanethol sulphonate (SPS)<sup>12,54,110</sup>. Failure to keep to this ratio may result in false negative culture results. SPS has an inhibitory effect on *Neisseria* species, anaerobic cocci, *Streptobacillus moniliformis* and *Mycoplasma hominis*<sup>127</sup>. The inhibitory effects of SPS may be reduced by the addition of gelatin to the broth<sup>128,129</sup>. The medium in some commercially available bottles is supplemented with materials which improve microbial recovery by adsorbing antimicrobial substances and which lyse WBCs to release organisms into the blood broth mixture<sup>12</sup>.

### Neutralisation of antimicrobial agents

At the time of blood culture sampling 28-63% of patients are in the process of receiving antimicrobial treatment which may have reduce organism recovery<sup>120</sup>. Media containing antibiotic inactivating resins and other adsorptive materials including charcoal have been developed to overcome the effect of antimicrobials<sup>120,121</sup>. Some media, however, rely on optimal blood-broth dilution for antimicrobial neutralisation<sup>121</sup>. Lysis-centrifugation techniques have been used, but there are conflicting reports concerning both their efficacy and the clinical importance of the increased isolation rates attributed to them<sup>130-133</sup>.

### Incubation time and temperature

A temperature of 35-37°C for 5-7 days is recommended for routine blood cultures<sup>12</sup>. Five days is usually sufficient incubation time for the recovery of most organisms if automated systems are used<sup>13,14</sup>. If conditions such as brucellosis are suspected, 2- 5 days incubation is usually sufficient. However, the incubation period may be extended to 10 days depending on culture medium used, and a terminal subculture may be required<sup>15-17</sup>. It is advisable that if these bacteria are suspected that all culture is suspended and the samples sent to the reference laboratory.

The incubation time may be extended for some cases of suspected endocarditis, for patients on antimicrobial therapy, or when infection with fungi (such as dimorphic fungi) or unusual, fastidious or slow growing organisms is suspected<sup>134</sup>. The increased

yield may be small for some organisms (HACEK) and specialised methods rather than extending incubation times may be more likely to improve recovery<sup>12,23,76,77,135</sup>.

### Agitation of media

Agitation usually increases the yield and early recovery of organisms from the aerobic bottle. Agitation of anaerobic bottles does not increase yield, whereas agitation of mycobacterial blood cultures decreases yield<sup>136,137</sup>. Continuous monitoring systems incorporate a variety of types and speeds of agitation. Semi-automated systems include an initial period of agitation for the aerobic bottles. Agitation of the aerobic bottle should be considered for conventional manual systems.

### Headspace atmosphere

Headspace atmosphere will depend on the system used, and may influence the rate of growth of some organisms. The headspace of aerobic bottles usually contains air with various concentrations of CO<sub>2</sub> and may require venting to increase the O<sub>2</sub> content. Depending on the system, the headspace of anaerobic bottles usually contains combinations of CO<sub>2</sub> and nitrogen.

### Subculture

If manual or semi-automated systems are used, subculture of both bottles in a set where only one bottle flags positive reveals both to be positive in about 50% of cases. It is probably unnecessary to subculture both for continuous monitoring systems. Subculture of anaerobic bottles via a sub-vent unit, loop or pipette will allow air into the headspace unless performed in an anaerobic cabinet and may adversely affect subsequent growth of anaerobic organisms. Diphasic systems have the advantage of using a simple closed subculture, achieved by tilting the bottle, but colony recognition may be impaired by the glass<sup>12</sup>.

### Blind or terminal subculture

Blind or terminal subculture is not routinely recommended for blood cultures if automated systems are used (manufacturers' instructions should be followed), but may be indicated for manual systems<sup>14,122,138</sup>. Some organisms such as *Neisseria* species, *Brucella* species, *Francisella* species, *H. influenzae* and *Legionella* species may give weak signals or may be present in blood culture media without showing visible signs of growth. Similar effects have been reported for *P. aeruginosa* and *Candida* species. Blind subculture (at appropriate containment level) of bottles from patients where clinical presentation or history is indicative of such organisms may be considered.

### Rapid Identification and Direct Sensitivity Testing<sup>94,139-142</sup>

Following conventional practice, identification and sensitivities of resistant organisms may not be available until 24-48hr post flagging positive; important information may therefore be significantly delayed, causing further delay in specific pathogen directed antimicrobial treatment<sup>7</sup>. Using rapid tests it is possible for identification and susceptibility results to be available within 24hr of flagging positive.

To reduce turnaround times, rapid identification and sensitivity tests should be performed in conjunction with routine methods where appropriate<sup>143</sup>. A variety of rapid identification and sensitivity methods have been evaluated; these include tube coagulase, antigen agglutination tests, molecular techniques and the recently developed Matrix Assisted Laser Desorption Ionisation Time-of-Flight (MALDI-

TOF)<sup>22,23,37,140,144,145</sup>. It is important to ensure that fresh cultures of pure single isolates are tested to avoid reporting misleading results.

Laboratories should follow manufacturers' instructions and all rapid tests must be validated and be shown to be fit for purpose prior to use.

## Rapid identification

### Antigen agglutination test

Antigen agglutination tests are used to test an unknown organism against known antisera. They are used for example in the serotyping of *Salmonella* species and the grouping of streptococci<sup>146,147</sup>. Refer to [TP 3 - Agglutination Test for \*Salmonella\* species](#). Lancefield grouping of streptococci direct from culture is useful as grouping is clinically significant and may affect antimicrobial treatment. Antigen testing of blood culture samples is also useful in confirming the presence of *S. pneumoniae* that has undergone autolysis. Refer to [ID 4 - Identification of \*Streptococcus\* species, \*Enterococcus\* species and Morphologically Similar Organisms](#).

### Coagulase test

Members of the genus staphylococcus are differentiated by the ability to clot plasma by the action of the enzyme coagulase. Rapid tests which differentiate between coagulase positive (including *S. aureus*) and coagulase negative staphylococci are well documented<sup>145,148-150</sup>. Tube coagulase, agglutination, conventional PCR techniques and molecular techniques with fluorescent labelled probes have also been shown to identify coagulase positive staphylococcus direct from blood culture. Variable sensitivities and specificities have been reported, and may be medium dependent<sup>12</sup>. Refer to [TP 10 – Coagulase Test](#).

### Automated identification methods

There are several automated systems available which are capable of performing identification (and sensitivity testing) on positive isolates using microtitre broth dilution techniques<sup>8,9,151</sup>. Comparative studies have shown that results from automated systems tested are reliable (particularly for Gram negative organisms) and can provide results in half the time required for conventional methods<sup>152</sup>.

### Molecular methods<sup>21,23,80,94,153</sup>

There is growing interest in the use of Polymerase Chain Reaction (PCR) tests and other nucleic acid amplification techniques (NAATs) for identification of bacteria from positive blood samples<sup>10,154</sup>. PCR targets conserved genes on the bacterial genome and enables the rapid identification of organisms including those that are slow to grow or are unculturable. Results are available within a short time frame, particularly if multiplex real-time PCR is used<sup>155</sup>. Several assays are available including pathogen specific assays (designed to detect one target in a positive blood sample), broad range assays (using primers that recognise conserved sequences encoding pathogen ribosomal DNA) and multiplex assays (designed to detect the most frequent pathogens in a single reaction)<sup>11</sup>.

### MALDI-TOF mass spectroscopy<sup>21</sup>

Recent developments in identification of bacteria, yeast and moulds include the use of 16s and 18s ribosomal protein profiles obtained by Matrix Assisted Laser Desorption Ionisation – Time of Flight (MALDI-TOF) mass spectroscopy<sup>155</sup>. Mass peaks achieved by the test strains are compared to those of known reference strains. It is possible for

an organism to be identified from an isolate within a short time frame and it is increasingly being used in laboratories to provide a robust identification system. The use of MALDI-TOF-MS in the identification of organisms directly from positive blood culture has been evaluated<sup>142,155-159</sup>. Studies have shown that direct identification of Gram positive bacteria (particularly staphylococci) is less reliable than Gram negative bacteria and that media composition (eg inclusion of charcoal) may affect identification<sup>155-159</sup>. Other studies have shown that rapid identification using MALDI-TOF leads to a decrease in the time to identification, and also results in an increase in the proportion of patients on appropriate antimicrobial treatment<sup>142</sup>.

### **Direct sensitivity**

To improve the quality of sensitivity testing there has been a general movement away from performing direct sensitivities on clinical samples. The British Society for Antimicrobial Chemotherapy (BSAC) does however recognise that the procedure is carried out in many laboratories as a means of providing rapid results<sup>160</sup>. To reduce turnaround times, it is recommended that direct sensitivity tests are performed on positive blood culture bottles where appropriate, recognising that sometimes different organisms may be identified from different bottles within a pair. Results should be interpreted with care, especially if the inoculum is lighter or heavier than the recommended semi-confluent growth.

### **Antibiotic disc diffusion method**

Antibiotic disc diffusion is not a novel method, but is rapid, easy to perform and inexpensive<sup>161</sup>. High rates of disparity have however been shown when comparing the disc method to automated methods<sup>9</sup>.

### **Minimal inhibitory concentration (MIC) tests**

Broth and agar dilution methods can be used to determine the lowest concentration of an antimicrobial agent able to inhibit growth under test conditions. The MIC value can be used to determine antimicrobial susceptibility of a specific strain against a particular antimicrobial drug. Antibiotic gradient strips which evaluate MIC have also recently been developed and may be used to acquire rapid results<sup>162</sup>.

Rapid results obtained by such means may influence patient management, improve laboratory work-flow and reduce costs. It is important that results of identification and sensitivity testing of blood cultures using commercial or other products should be viewed with caution unless they have been validated. Where the culture is mixed or the inoculum level is incorrect sensitivity tests should be repeated<sup>160</sup>.

## **Contamination**

Contamination of blood cultures complicates interpretation and can lead to unnecessary antimicrobial therapy and increased costs. In general, contamination target rates are set at less than 3%<sup>103,163,164</sup>. Several criteria are used to differentiate between contamination and true bacteraemia and to determine the clinical significance of a positive result. These include the identity of the organism, the number of positive sets, the number of positive bottles within a set, quantity of growth, and clinical and laboratory data (including source of culture)<sup>59,165</sup>. Prevention of contamination can be achieved through appropriate skin and bottle preparation, obtaining cultures from peripheral venepuncture instead of vascular catheters, and through training and intervention measures<sup>163,165,166</sup>.



## Technical Information/Limitations

---

### Limitations of UK SMIs

The recommendations made in UK SMIs are based on evidence (eg sensitivity and specificity) where available, expert opinion and pragmatism, with consideration also being given to available resources. Laboratories should take account of local requirements and undertake additional investigations where appropriate. Prior to use, laboratories should ensure that all commercial and in-house tests have been validated and are fit for purpose.

### Specimen Containers<sup>167,168</sup>

SMIs use the term “CE marked leak-proof container” to describe containers bearing the CE marking used for the collection and transport of clinical specimens. The requirements for specimen containers are given in the EU in vitro Diagnostic Medical Devices Directive (98/79/EC Annex 1 B 2.1) which states: “The design must allow easy handling and, where necessary, reduce as far as possible contamination of, and leakage from, the device during use and, in the case of specimen receptacles, the risk of contamination of the specimen. The manufacturing processes must be appropriate for these purposes”.

### Pre-Incubation of Blood Cultures

The recognition that certain non-fermenting, Gram negative bacteria such as *Pseudomonas aeruginosa*, *Streptococcus* species and yeasts may not be detected in continuous monitoring blood culture systems if pre-incubated at 35-37°C has had a significant effect on laboratory practice, resulting in many laboratories storing and transporting delayed samples at room temperature<sup>2,169,170</sup>.

These organisms may fail to trip the threshold algorithm of the continuous monitoring blood culture machine. Detection of their presence in positive blood cultures is dependent upon biochemical changes during the growth phase. When pre-incubation has been sufficiently long for the organism to have gone through the growth phase and be in the stationary or decline phase, bottles containing such organisms will not register as a positive on the machine.

It is estimated that 2-5% of positive samples may be missed if bottles are pre-incubated. However, if stored at room temperature prior to loading, the time from collection to a positive result being flagged (time to positivity or TTP) for many organisms may be doubled or tripled<sup>2,4,5,35</sup>.

All delayed cultures should be inspected on receipt for signs of growth including yellowing of the sensor, haemolysis, gas production or turbidity. If microbial growth is confirmed by Gram stain, the bottle should be treated as positive and subcultured as appropriate.

Laboratories should investigate peer reviewed literature and clinical laboratory textbooks and validate all methods used.

### Inconsistent Results

#### Positive appearance/flag positive with positive Gram stained film, but negative subculture

This may occur with *Abiotrophia* species (nutritionally variant streptococci), *S. pneumoniae* which have undergone a degree of autolysis, and fastidious organisms which are unable to grow on routine solid culture media<sup>71,171,172</sup>. Additional or supplemented media, prolonged incubation or alternative growth atmosphere should be considered, depending on the microscopy and clinical indications. Organisms may include:

- *Campylobacter* species
- *Helicobacter* species
- Capnophilic organisms
- Slow-growing anaerobes

Some media are reported to reduce the autolysis of *S. pneumoniae*<sup>173</sup>. If *S. pneumoniae* is suspected, either by microscopy or clinically, it may be useful to inoculate some of the lysed blood/broth mixture to fresh blood culture bottles in an attempt to recover viable organisms or consider direct antigen testing by a validated method on the broth bottle.

### **Positive appearance/flag positive with negative Gram stained film, but negative subculture**

It is important to examine the growth curve on automated systems to exclude the possibility of a false negative culture before assuming a false positive flag.

Reasons for false positivity are often multifactorial. On automated systems they may include problems with equipment, threshold values set too low, exceeding the maximum recommended blood volume, or testing blood with high leucocyte counts. On conventional systems, turbidity may be related to the appearance of the patient's serum rather than microbial growth. However, if growth curves indicate microbial growth, then an alternative stain such as carbol fuchsin, Giemsa or Sandiford may be required to demonstrate the presence and morphology of the organisms involved<sup>174</sup>. This may give guidance for the selection of appropriate media for subcultures.

### **Negative appearance/negative flag with positive Gram stained film and positive subculture.**

Refer to section on subculture.

# 1 Safety Considerations<sup>167,168,175-189</sup>

## 1.1 Specimen Collection, Transport and Storage<sup>167,168,175-178</sup>

Use aseptic technique.

Collect specimens in appropriate CE marked leak-proof containers (according to manufacturers' instruction if using a continuous monitoring blood culture system) and transport in sealed plastic bags.

Inspect the blood culture bottles for damage.

Ensure that the blood culture bottles have not exceeded their expiry date.

Do not re-sheathe needles.

Compliance with postal, transport and storage regulations is essential.

## 1.2 Specimen Processing<sup>167,168,175-189</sup>

Containment Level 2.

All specimens should be processed at Containment Level 2 unless infection with a Hazard Group 3 organism (eg *Mycobacterium tuberculosis*, *Brucella* species, *Francisella* species, *Y. pestis*, *B. mallei*, *B. pseudomallei*) is suspected, or when subculturing blood culture bottles from suspected cases of typhoid or paratyphoid fever. In these situations work should be performed in a microbiological safety cabinet under Containment Level 3 conditions.

Laboratory procedures that give rise to infectious aerosols (including venting of blood culture bottles) must be conducted in a microbiological safety cabinet (MSC)<sup>181</sup>. Ideally all blood cultures should be subcultured in a MSC because clinical details may be lacking and may not highlight the possibility of Hazard Group 3 organisms.

*N. meningitidis* causes severe and sometimes fatal disease. Laboratory acquired infections have been reported. The organism infects primarily by the respiratory route. An effective vaccine is available for some meningococcal groups.

*N. meningitidis* is a Hazard Group 2 organism and the processing of diagnostic samples can be carried out at Containment Level 2.

Due to the severity of the disease and the risks associated with generating aerosols of the organism, any manipulation of suspected isolates of *N. meningitidis* should always be undertaken in a microbiological safety cabinet until *N. meningitidis* has been ruled out (as must any laboratory procedure giving rise to infectious aerosols).

Be aware that some of the Hazard Group 3 fungi are thermally dimorphic and will grow as yeast forms in blood culture bottles and sub-cultures at 37°C, but as the highly infective mould form when sub-cultured to agar incubated at 28-30°C. Care should be taken with yeast isolates if there is a relevant travel history, especially in HIV-infected individuals.

The use of sharp objects should be avoided wherever possible. The use of airway needles for venting and sub-vent units for the subculture of bottles are preferred, unless the system uses a screw cap in which case the use of a plastic pipette is recommended.

Load bottles from "High Risk" patients according to manufacturers' recommendations and local protocols.

Refer to current guidance on the safe handling of all organisms documented in this SMI.

The above guidance should be supplemented with local COSHH and risk assessments.

## 2 Specimen Collection

---

### 2.1 Type of Specimens

Blood

### 2.2 Optimal Time and Method of Collection<sup>190</sup>

For safety considerations refer to Section 1.1.

Sampling of blood should be carried out according to Department of Health guidance<sup>103</sup>.

Collect specimens before antimicrobial therapy where possible<sup>190</sup>.

Collect specimens as soon as possible after the onset of clinical symptoms. Although blood can be sampled at any time, drawing blood at, or as soon as possible after a fever spike is optimal, except in endocarditis where timing is less important<sup>111</sup>.

Collect specimens in appropriate CE marked leak-proof containers and place in sealed plastic bags. Appropriate blood culture bottles must be used for specific machines when using continuous monitoring blood culture systems and manufacturers' instructions should be followed.

Consider the use of a single low volume bottle for small volumes of blood. If a low volume bottle is unavailable, use a single aerobic bottle. If necrotising enterocolitis is suspected and sufficient blood is obtained, inoculate a 'low volume' and an anaerobic bottle.

**Note:** The use of iodine-based disinfectants is not recommended for disinfection of the butyl rubber septum for some commercial systems as this may affect the septum's integrity.

**Note:** The use of blood collection adapters without 'winged' blood collection sets is not recommended as it is not possible to accurately judge the sample volume and there may be the potential for backflow of blood culture media to patient veins.

**Note:** If blood for other tests such as blood gases or ESR is to be taken at the same venepuncture, the blood culture bottles should be inoculated first to avoid contamination. It is preferable to take blood for culture separately.

### 2.3 Adequate Quantity and Appropriate Number of Specimens<sup>190</sup>

Blood culture is a culture of blood collected from a single venepuncture site inoculated to one or multiple bottles.

A blood culture set is defined as one aerobic and one anaerobic bottle. For infants and neonates, a single aerobic bottle may be requested.

## Quantity

### Adults

Preferably, a volume of 20-30mL for each blood culture set should be taken.

**Note:** More than 2 bottles per set may be indicated.

### Children and neonates

No more than 1% of the total blood volume.

**Note:** Do not exceed the manufacturer's recommended maximum volume for each bottle. Different manufacturers market different bottle formats.

**Note:** If the volume of blood is insufficient for two bottles, the aerobic bottle should be inoculated first and then the rest inoculated to an anaerobic bottle.

## Number

The number and frequency of specimen collections is dependent on the clinical condition of the patient.

Take two consecutive sets from two separate venepuncture sites during any 24hr period for each septic episode<sup>110</sup>. For neonates, take a single aerobic bottle or special low volume bottle.

Take two sets during the first hour in cases of severe sepsis prior to commencing antibiotic treatment, provided this does not significantly delay antibiotic administration<sup>31</sup>.

Take at least three sets during a 24hr period where the patient has suspected infective endocarditis.

## 3 Specimen Transport and Storage<sup>167,168</sup>

---

### 3.1 Optimal Transport and Storage Conditions

For safety considerations refer to Section 1.1.

Specimens should be transported and processed as soon as possible<sup>190</sup>.

Inoculated bottles should be loaded to continuous monitoring blood culture systems as soon as possible, and within a maximum of 4 hours<sup>1,2,4-6</sup>.

It is recommended that laboratory management establish and manage transportation of samples to ensure specimens arrive within an appropriate time frame dependent on specimen type and tests required, and to prevent sample deterioration<sup>3</sup>.

Samples should not be refrigerated<sup>190</sup>.

Laboratory workers should be aware that delayed sample bottles should be checked for signs of growth prior to loading. If signs of growth are visible a Gram stain should be performed and the bottle subcultured<sup>169,170</sup>.

## 4 Specimen Processing/Procedure<sup>167,168</sup>

---

### 4.1 Test Selection

N/A

## 4.2 Appearance

Inspect the bottles visually for evidence of microbial growth.

## 4.3 Sample Preparation

### 4.3.1 Pre-treatment

N/A

### 4.3.2 Specimen processing

Incubate the bottles at 35-37°C for 5-7 days.

## Standard

### Positive bottles from all systems

Disinfect the septum of the blood culture bottle with the appropriate disinfectant and allow to dry.

Withdraw a few drops of blood/broth mixture (or buffy coat layer) with a sub-vent unit or plastic pipette, depending on bottle type, and inoculate one drop on to each agar plate.

For the isolation of individual colonies, spread inoculum with a sterile loop ([Q 5 – Inoculation of Culture Media for Bacteriology](#)).

Subculture for direct susceptibility testing. If the correct inoculum is not achieved the test should be repeated.

**Note:** In order to minimise the risk of autolysis of certain organisms such as *S. pneumoniae*, bottles should be subcultured as soon as possible after a positive flag is detected<sup>173</sup>.

### Positive bottles from manual systems

Subculture all bottles of the set as described above, even if only one bottle appears positive.

### Negative bottles from continuous monitoring systems

Blind subculture bottles from patients if clinically indicated.

### Negative bottles from manual systems

Perform blind subculture for any aerobic bottle that appears negative after 24-48hr<sup>191</sup>.

## Supplementary

### Flag/appearance positive, but culture negative - all automated systems

Examine the growth curve.

If possible, exclude the possibility of false positives due to high white cell counts.

In relation to the clinical presentation and Gram stained film result, consider the possibility of a nutritionally dependent, slow growing or fastidious organism.

Subculture to appropriate media or, if uncertain as to possible aetiology, perform supplementary culture as indicated in Section 4.5.1. Refer to Technical Information/Limitations for further information.

## 4.4 Microscopy

### Positive bottles - all systems

Perform microscopy on broth from any bottle which “flags” positive or which is visually positive (bowed septum, blood lysed or indicator colour change).

If using a diphasic medium, prepare a Gram stained film from both the buffy layer and the agar surface.

1. Mix the bottle gently by inversion if this has not already been done automatically.

**Note:** Some systems may not require mixing, but manufacturers may recommend subculture of the buffy coat layer.

2. Disinfect the septum of the blood culture bottle with the appropriate disinfectant and allow to dry.
3. With a sub-vent unit or plastic pipette, depending on bottle type, remove a few drops of blood/broth mixture (or buffy coat layer) and place on a clean microscope slide.

**Note:** Refer to manufacturers’ instructions with respect to preparing smears from charcoal-containing bottles.

4. Spread with a sterile loop to make a thin smear for Gram staining.

**Note:** Gram negative organisms may be seen more easily if Sandiford or carbol fuchsin counterstain is used<sup>174</sup> ([TP 39 – Staining Procedures](#)).

If organisms are not seen on microscopy:

1. Investigate the growth curve (automated systems). If growth parameters indicate positive microbial growth, the preparation of further films with alternative stains may be useful.
2. Subculture to agar plates (see 4.5.1), and return the bottle to the automated system, according to manufacturer's instructions, for further incubation and testing.
3. Consider *Mycobacterium* species. [B 40 – Investigation of Specimens for \*Mycobacterium\* Species](#).

On automated systems false positive signals may be caused by excess blood volume or a high white cell count.

## 4.5 Culture and Investigation

Inoculate each agar plate using a sterile pipette ([Q 5 - Inoculation of Culture Media for Bacteriology](#)).

For the isolation of individual colonies, spread inoculum with a sterile loop.

## 4.5.1 Culture media, conditions and organisms

Clinical details/ conditions	Specimen	Standard media	Incubation			Cultures read	Target organism(s)
			Temp °C	Atmos	Time		
All clinical conditions	Blood	Blood agar†	35-37	5-10% CO <sub>2</sub>	40-48hr*	Daily	Any organism may be significant
		Fastidious anaerobe agar	35-37	anaerobic	40-48hr*	≥40hr and up to 5d	Any organism may be significant
For these situations, add the following:							
Clinical details/ conditions	Specimen	Supplementa ry media	Incubation			Cultures read	Target organism(s)
			Temp °C	Atmos	Time		
Suspected meningo-coccaemia or meningitis  Small Gram negative rods or diplococci seen on microscopy	Blood	Chocolate agar†	35-37	5-10% CO <sub>2</sub>	40-48hr	Daily	<i>Haemophilus</i> species <i>N. meningitidis</i> <i>N. gonorrhoeae</i>
Gram negative rods seen on microscopy	Blood	MacConkey/ CLED agar or Chromogenic agar	35-37	air	16-24hr	≥16hr	Enterobacteriaceae  Non-fermentative organism  <i>Pseudomonas</i> species
Microscopy suggestive of mixed or anaerobic infection	Blood	Neomycin fastidious anaerobe agar with metronidazole 5µg disc	35-37	anaerobic	5-7d	≥40hr and at 5d	Anaerobes
Systemic fungal infection#	Blood	Sabouraud agar	28-30	air	5d	2d and at 5d	Yeast  Mould
Primary culture negative and positive growth curve‡  (subculture all bottles)	Blood	Blood agar	35-37	micro-aerobic	5d	≥3d and at 5d	<i>Campylobacter</i> species  <i>Helicobacter</i> species
		Blood agar with streak of <i>S. aureus</i> (NCTC 6571)	35-37	5-10% CO <sub>2</sub>	40-48hr	≥40hr	<i>Abiotrophia</i> species
		Fastidious anaerobe agar	35-37	anaerobic	5d	≥40hr and at 5d	Cysteine-dependent anaerobic organisms
		MacConkey/ CLED agar	35-37	air	16-24hr	≥16hr	Cysteine-dependent organisms



## Investigation of Blood Cultures (for Organisms other than *Mycobacterium* species)

Other organisms for consideration – *Mycobacterium* (B 40) and *Brucella* species: also consider organisms that might be involved in deliberate release.

†an optochin disc may be added if streptococci seen on microscopy.

\*incubation may be extended to up to 5 days if false negative likely or as clinically indicated; in such cases plates should be read at  $\geq 40$  hours and left in the incubator/cabinet for up to 5 days.

#where clinically indicated, blood culture bottles may require an extended incubation of up to three weeks for *Cryptococcus* species and up to six weeks for *Histoplasma* species<sup>19,192-194</sup>.

‡other organisms may need to be considered.

Rapid tests such as antigen detection or PCR should be performed according to manufacturers' instructions.

### 4.6 Identification

Refer to individual SMIs for organism identification.

#### Minimum level in the laboratory

All clinically significant isolates should be identified to species level.

**Note:** Any organism considered to be a contaminant may not require identification to species level.

It is recommended that clinically significant isolates are retained for at least one week. Storage of isolates on slopes of appropriate media or at  $-20^{\circ}\text{C}$  to  $-80^{\circ}\text{C}$  for longer periods may need to be considered if further testing is likely (eg typing isolates from nosocomial infection).

### 4.7 Antimicrobial Susceptibility Testing

To reduce turnaround times, it is recommended that direct sensitivity tests are performed on all positive blood culture isolates where appropriate.

Refer to [British Society for Antimicrobial Chemotherapy \(BSAC\)](#) and/or [EUCAST](#) guidelines.

### 4.8 Referral for Outbreak Investigations

N/A

### 4.9 Referral to Reference Laboratories

For information on the tests offered, turnaround times, transport procedure and the other requirements of the reference laboratory [click here for user manuals and request forms](#).

Organisms with unusual or unexpected resistance or associated with a laboratory or clinical problem, or anomaly that requires elucidation, should be sent to the appropriate reference laboratory.

Contact appropriate devolved national reference laboratory for information on the tests available, turnaround times, transport procedure and any other requirements for sample submission:

England and Wales

<https://www.gov.uk/specialist-and-reference-microbiology-laboratory-tests-and-services>

Scotland

<http://www.hps.scot.nhs.uk/reflab/index.aspx>

Northern Ireland

<http://www.publichealth.hscni.net/directorate-public-health/health-protection>

## 5 Reporting Procedure

---

Locally agreed policies for the release of results should be written based on local LIMS and user requirements.

### 5.1 Microscopy

#### Gram stain

Report organism detected.

#### Other supplementary stains

Organisms that are detected should be reported verbally where significant (in addition, written reports may be required by local protocols).

##### 5.1.1 Microscopy reporting time

Positive results should be released immediately, within a two hour period, following local policy. Written or computer generated reports should follow preliminary/verbal reports within 24hr.

### 5.2 Culture

The following results should be reported:

- all organisms which are isolated (with comment if isolate is of doubtful significance)
- absence of growth
- results of supplementary investigations

##### 5.2.1 Culture reporting time

Preliminary positive culture reports should be telephoned or sent electronically stating, if appropriate, that a further report will be issued. Final written or computer generated reports should follow preliminary/verbal reports on the same day as confirmation where possible, and within a maximum of 24hr<sup>24</sup>.

Preliminary negative results should be reported at 36hr from collection for neonates and 48hr for all other patients (or as per local agreement)<sup>18,20</sup>. It is anticipated that preliminary negative reports will be generated automatically to closely reflect the true incubation time. Final reports should be generated within five days of receipt in the laboratory (greater if extended incubation required, or if isolates are sent to a

reference laboratory for confirmation), as soon as possible and within a maximum of 48hr after the preliminary report.

Clinically urgent results should be telephoned or sent electronically or according to local protocols.

### 5.3 Antimicrobial Susceptibility Testing

Report susceptibilities as clinically indicated. Prudent use of antimicrobials according to local and national protocols is recommended.

## 6 Notification to PHE<sup>195,196</sup> or Equivalent in the Devolved Administrations<sup>88-91</sup>

---

The Health Protection (Notification) regulations 2010 require diagnostic laboratories to notify Public Health England (PHE) when they identify the causative agents that are listed in Schedule 2 of the Regulations. Notifications must be provided in writing, on paper or electronically, within seven days. Urgent cases should be notified orally and as soon as possible, recommended within 24 hours. These should be followed up by written notification within seven days.

For the purposes of the Notification Regulations, the recipient of laboratory notifications is the local PHE Health Protection Team. If a case has already been notified by a registered medical practitioner, the diagnostic laboratory is still required to notify the case if they identify any evidence of an infection caused by a notifiable causative agent.

Notification under the Health Protection (Notification) Regulations 2010 does not replace voluntary reporting to PHE. The vast majority of NHS laboratories voluntarily report a wide range of laboratory diagnoses of causative agents to PHE and many PHE Health protection Teams have agreements with local laboratories for urgent reporting of some infections. This should continue.

**Note:** The Health Protection Legislation Guidance (2010) includes reporting of Human Immunodeficiency Virus (HIV) & Sexually Transmitted Infections (STIs), Healthcare Associated Infections (HCAs) and Creutzfeldt–Jakob disease (CJD) under 'Notification Duties of Registered Medical Practitioners': it is not noted under 'Notification Duties of Diagnostic Laboratories'.

<https://www.gov.uk/government/organisations/public-health-england/about/our-governance#health-protection-regulations-2010>

Other arrangements exist in [Scotland](#)<sup>88,89</sup>, [Wales](#)<sup>90</sup> and [Northern Ireland](#)<sup>91</sup>.

## Appendix 1: Critical Control Points in Blood Culture Investigation


By breaking down the blood culture process, it is possible to identify critical control points where there may be delays or the potential to improve turnaround times (TAT)<sup>2</sup>.

The term TAT, in this context, refers to the time taken from blood culture collection to the time of reporting. Laboratory TAT refers to the time from receipt of the sample in the laboratory to reporting of results. The time taken to achieve each of the following stages of the process has an effect on the overall TAT.

- Time from collection to receipt within the laboratory<sup>2,6</sup> - Transport Time (TT)
- Time from receipt to loading on blood culture system<sup>2</sup>
- Time from loading to registering positive<sup>97,197</sup> - Time to Detection (TTD)
- Time from flagging positive to identification and susceptibility results<sup>4,24</sup>
- Time from identification and susceptibility results to reporting

Excluding the time from placement on the blood culture machine to detection (TTD), each stage of the process is dependent on multiple external factors including transport infrastructure, prioritisation and speed of processing by staff, out of hours service delivery and timely communication of positive identification and susceptibility results to medical staff. Once the culture is placed on the blood culture machine, there is little that can be done to speed up the process until sufficient growth has occurred for the bottles to flag positive. The time from flagging a positive result to identification and susceptibility results can be further subdivided in two stages; the time from flagging a positive to removal from the culture machine, and the time from removal to results of Gram stain, identification and sensitivities. Preliminary results may be given verbally prior to final report generation.

### Timeline - Critical Control Points<sup>2</sup>



Decreasing TAT leads to improved clinical outcomes because positive blood culture results provide a second opportunity via reports and clinical liaison to optimise antibiotic treatment where initial empirical therapy has been suboptimal<sup>25,35</sup>.


## Appendix 2: Therapeutic Window<sup>25,28,35</sup>

For each patient there is a period of time within which the infection and the patient can both be successfully treated, this can be thought of as the 'Therapeutic Window'. There comes a point outside the window period at which, even though the infection may be brought under control or eradicated, the patient will not survive as the resultant inflammatory cascades or organ damage has gone beyond a stage at which it is reversible<sup>26</sup>. The aim is therefore to deliver appropriate therapy including antibiotics within the window period. The size of the therapeutic window varies enormously and may be very short or indefinitely long dependent on the organisms and patient involved. The optimal approach involves early prescription of broad-spectrum antibiotics followed by timely responses to both microbiological and clinical results as and when they become available<sup>25</sup>.

The following four scenarios demonstrate the potential influence of blood culture results on patient outcome<sup>28</sup>:

### 1. Appropriate treatment is received within the therapeutic window and the patient survives


The therapeutic window outlines a period of time within which both the infection and the patient can be successfully treated. The size of the therapeutic window varies enormously. For example in a young patient with cystitis, the window may appear indefinitely long. At the other extreme, in the very septic patient, the therapeutic window may be very short. Any delay beyond this in initiating appropriate treatment is associated with an adverse outcome. Sepsis pathways recognise the importance of prompt antibiotic therapy including this as a key action.



### 2. The patient receives inappropriate empirical antibiotic throughout the therapeutic window and does not survive


The duration of the therapeutic window may in this instance have been very short extending up to several days. Sepsis evolves over a period of time. Thus when the patient was first seen their condition may have been stable with a relatively long therapeutic window. Incorrect antibiotics were prescribed and time is lost as it is difficult to judge their effectiveness in the first 24-48 hours. For a variety of reasons the appropriate treatment is not delivered, and the patient dies.

## Investigation of Blood Cultures (for Organisms other than *Mycobacterium* species)




### 3. The patient receives appropriate treatment outside of the therapeutic window and does not survive

The results of a blood culture identify that the patient is receiving inappropriate treatment. However, the blood culture result is received too late, falling outside the 'window of opportunity'. Even though appropriate treatment is initiated the patient's fate has already been sealed. Whereas the bacterial infection may be eradicated by antibiotics the effect of the infection on the patient has become irreversible.




### 4. The patient receives appropriate treatment within the therapeutic window and survives

The blood culture result has been received within the therapeutic window resulting in institution of appropriate therapy and a successful outcome. The patient's clinical condition was stable on admission but deteriorated with incorrect treatment rapidly approaching the end of the therapeutic window.



In scenarios three and four 'critical time' periods are illustrated, the time between the end of the window and the blood culture result being available. The critical time period is highly variable, but it is known that it could be very short for some patients. In contrast processing a blood culture rapidly (scenario four) can expedite a result by 24 hours or more, easily enough to shift the administration of appropriate therapy back within the window period for some patients.

## Appendix 3: Investigation of Blood Cultures (for Organisms other than *Mycobacterium* species)



## References

---

1. Saito T, Iinuma Y, Takakura S, Nagao M, Matsushima A, Shirano M, et al. Delayed insertion of blood culture bottles into automated continuously monitoring blood culture systems increases the time from blood sample collection to the detection of microorganisms in bacteremic patients. *J Infect Chemother* 2009;15:49-53.
2. van der Velden LB, Vos FJ, Mouton JW, Sturm PD. Clinical impact of preincubation of blood cultures at 37 degrees C. *J Clin Microbiol* 2011;49:275-80.
3. Clinical Pathology Accreditation (UK) Ltd. Standards for the Medical Laboratory. 2010.
4. Janapatla RP, Yan JJ, Chien ML, Chen HM, Wu HM, Wu JJ. Effect of overnight storage of blood culture bottles on bacterial detection time in the BACTEC 9240 blood culture system. *J Microbiol Immunol Infect* 2010;43:126-32.
5. Lemming L, Holt HM, Petersen IS, Ostergaard C, Bruun B. Bactec 9240 blood culture system: to preincubate at 35 degrees C or not? *Clin Microbiol Infect* 2004;10:1089-91.
6. Ronnberg C, Mildh M, Ullberg M, Ozenci V. Transport time for blood culture bottles: underlying factors and its consequences. *Diagn Microbiol Infect Dis* 2013;76:286-90.
7. Kerremans JJ, Verboom P, Stijnen T, Hakkaart-van Roijen L, Goessens W, Verbrugh HA, et al. Rapid identification and antimicrobial susceptibility testing reduce antibiotic use and accelerate pathogen-directed antibiotic use. *J Antimicrob Chemother* 2008;61:428-35.
8. Kerremans JJ, Goessens WH, Verbrugh HA, Vos MC. Accuracy of identification and susceptibility results by direct inoculation of Vitek 2 cards from positive BACTEC cultures. *Eur J Clin Microbiol Infect Dis* 2004;23:892-8.
9. Edelmann A, Pietzcker T, Wellinghausen N. Comparison of direct disk diffusion and standard microtitre broth dilution susceptibility testing of blood culture isolates. *J Med Microbiol* 2007;56:202-7.
10. Dark P, Dunn G, Chadwick P, Young D, Bentley A, Carlson G, et al. The clinical diagnostic accuracy of rapid detection of healthcare-associated bloodstream infection in intensive care using multipathogen real-time PCR technology. *BMJ Open* 2011;1:e000181.
11. Paolucci M, Landini MP, Sambri V. Conventional and molecular techniques for the early diagnosis of bacteraemia. *Int J Antimicrob Agents* 2010;36 Suppl 2:S6-16.
12. Reimer LG, Wilson ML, Weinstein MP. Update on detection of bacteremia and fungemia. *Clin Microbiol Rev* 1997;10:444-65.
13. Masterson KC, McGowan JE, Jr. Detection of positive blood cultures by the Bactec NR660. The clinical importance of five versus seven days of testing. *Am J Clin Pathol* 1988;90:91-4.
14. Hardy DJ, Hulbert BB, Migneault PC. Time to detection of positive BacT/Alert blood cultures and lack of need for routine subculture of 5- to 7-day negative cultures. *J Clin Microbiol* 1992;30:2743-5.
15. Kurtoglu MG, Bozkurt H, Tuncer O, Kesli R, Berktaş M. Distribution, optimum detection time and antimicrobial susceptibility rates of the microorganisms isolated from blood cultures over a 4-year time period in a Turkish university hospital and a review of the international literature. *J Int Med Res* 2008;36:1261-72.
16. Ozkurt Z, Erol S, Tasyaran MA, Kaya A. Detection of *Brucella melitensis* by the BacT/Alert automated system and *Brucella* broth culture. *Clin Microbiol Infect* 2002;8:749-52.



## Investigation of Blood Cultures (for Organisms other than *Mycobacterium* species)

17. Sumerkan B, Gokahmetoglu S, Esel D. Brucella detection in blood: comparison of the BacT/Alert standard aerobic bottle, BacT/Alert FAN aerobic bottle and BacT/Alert enhanced FAN aerobic bottle in simulated blood culture. *Clin Microbiol Infect* 2001;7:369-72.
18. National Institute for Healthcare and Clinical Excellence. Antibiotics for early-onset neonatal infection: antibiotics for the prevention and treatment of early-onset neonatal infection. 2012.
19. Labarca JA, Wagar EA, Grasmick AE, Kokkinos HM, Bruckner DA. Critical evaluation of 4-week incubation for fungal cultures: is the fourth week useful? *J Clin Microbiol* 1998;36:3683-5.
20. Kumar Y, Qunibi M, Neal TJ, Yoxall CW. Time to positivity of neonatal blood cultures. *Arch Dis Child Fetal Neonatal Ed* 2001;85:F182-F186.
21. Stefani S. Diagnostic techniques in bloodstream infections: where are we going? *Int J Antimicrob Agents* 2009;34 Suppl 4:S9-12.
22. Rowther FB, Rodrigues CS, Deshmukh MS, Kapadia FN, Hegde A, Mehta AP, et al. Prospective comparison of eubacterial PCR and measurement of procalcitonin levels with blood culture for diagnosing septicemia in intensive care unit patients. *J Clin Microbiol* 2009;47:2964-9.
23. Fenollar F, Raoult D. Molecular diagnosis of bloodstream infections caused by non-cultivable bacteria. *Int J Antimicrob Agents* 2007;30 Suppl 1:S7-15.
24. Hautala T, Syrjala H, Lehtinen V, Kauma H, Kauppila J, Kujala P, et al. Blood culture Gram stain and clinical categorization based empirical antimicrobial therapy of bloodstream infection. *Int J Antimicrob Agents* 2005;25:329-33.
25. Deresinski S. Principles of Antibiotic Therapy in Severe Infections: Optimizing the Therapeutic Approach by Use of Laboratory and Clinical Data. *Clinical Infectious Diseases* 2007;45:S177-S183.
26. Berild D, Mohseni A, Diep LM, Jensenius M, Ringertz SH. Adjustment of antibiotic treatment according to the results of blood cultures leads to decreased antibiotic use and costs. *J Antimicrob Chemother* 2006;57:326-30.
27. Sprung CL. Definitions of sepsis--have we reached a consensus? *Crit Care Med* 1991;19:849-51.
28. Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. *Clin Infect Dis* 1997;24:584-602.
29. Jumaa PA, Chattopadhyay B. Pseudobacteraemia. *J Hosp Infect* 1994;27:167-77.
30. Noskin GA, Suriano T, Collins S, Sesler S, Peterson LR. *Paenibacillus macerans* pseudobacteremia resulting from contaminated blood culture bottles in a neonatal intensive care unit. *Am J Infect Control* 2001;29:126-9.
31. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. *Intensive Care Med* 2008;34:17-60.
32. Al MM, Darouiche RO. Sepsis syndrome, bloodstream infections, and device-related infections. *Med Clin North Am* 2012;96:1203-23.
33. Annane D, Bellissant E, Cavaillon JM. Septic shock. *Lancet* 2005;365:63-78.
34. Cohen J. Sepsis. *Medicine* 2009;37:562-5.

## Investigation of Blood Cultures (for Organisms other than *Mycobacterium* species)

35. Kerremans JJ, van der Bij AK, Goessens W, Verbrugh HA, Vos MC. Immediate incubation of blood cultures outside routine laboratory hours of operation accelerates antibiotic switching. *J Clin Microbiol* 2009;47:3520-3.
36. Daniels R. Surviving the first hours in sepsis: getting the basics right (an intensivist's perspective). *Journal of Antimicrobial Chemotherapy* 2011;66:ii11-ii23.
37. Paolucci M, Landini MP, Sambri V. How can the microbiologist help in diagnosing neonatal sepsis? *Int J Pediatr* 2012;120-39.
38. Edmond K, Zaidi A. New approaches to preventing, diagnosing, and treating neonatal sepsis. *PLoS Med* 2010;7:e1000213.
39. Brook I. The role of anaerobic bacteria in bacteremia. *Anaerobe* 2010;16:183-9.
40. Finelli L, Livengood JR, Saiman L. Surveillance of pharyngeal colonization: detection and control of serious bacterial illness in low birth weight infants. *Pediatr Infect Dis J* 1994;13:854-9.
41. Lee PY, Holliman RE, Davies EG. Surveillance cultures on neonatal intensive care units. *J Hosp Infect* 1995;29:233-6.
42. Guerti K, Devos H, Ieven MM, Mahieu LM. Time to positivity of neonatal blood cultures: fast and furious? *J Med Microbiol* 2011;60:446-53.
43. Ispahani P, Pearson NJ, Greenwood D. An analysis of community and hospital-acquired bacteraemia in a large teaching hospital in the United Kingdom. *Q J Med* 1987;63:427-40.
44. Plummer M, Schoch PE. *Rothia dentocariosa* bacteremia. *Clinical Microbiology Newsletter* 1995;17:22-4.
45. Auzias A, Bollet C, Ayari R, Drancourt M, Raoult D. *Corynebacterium freneyi* bacteremia. *J Clin Microbiol* 2003;41:2777-8.
46. Roberts FJ. Nontyphoidal, nonparatyphoidal salmonella septicemia in adults. *Eur J Clin Microbiol Infect Dis* 1993;12:205-8.
47. Wilks D, Jacobson SK, Lever AM, Farrington M. Fatal melioidosis in a tourist returning from Thailand. *J Infect* 1994;29:87-90.
48. Collazos J, de Miguel J, Ayarza R. *Moraxella catarrhalis* bacteremic pneumonia in adults: two cases and review of the literature. *Eur J Clin Microbiol Infect Dis* 1992;11:237-40.
49. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. *Clin Infect Dis* 1995;20:1531-4.
50. Warnock EW, III, MacMath TL. Primary *Vibrio vulnificus* septicemia. *J Emerg Med* 1993;11:153-6.
51. Khan AM, Albert MJ, Sarker SA, Bhattacharya MK, Azad AK. Septicemia due to *Vibrio cholerae* 0139 Bengal. *Diagn Microbiol Infect Dis* 1995;22:337-8.
52. Bonatti H, Rossboth DW, Nachbaur D, Fille M, Aspöck C, Hend I, et al. A series of infections due to *Capnocytophaga* spp in immunosuppressed and immunocompetent patients. *Clin Microbiol Infect* 2003;9:380-7.
53. Fenner L, Widmer AF, Straub C, Frei R. Is the incidence of anaerobic bacteremia decreasing? Analysis of 114,000 blood cultures over a ten-year period. *J Clin Microbiol* 2008;46:2432-4.
54. Mylotte JM, Tayara A. Blood cultures: clinical aspects and controversies. *Eur J Clin Microbiol Infect Dis* 2000;19:157-63.

## Investigation of Blood Cultures (for Organisms other than *Mycobacterium* species)

55. Riley JA, Heiter BJ, Bourbeau PP. Comparison of recovery of blood culture isolates from two BacT/ALERT FAN aerobic blood culture bottles with recovery from one FAN aerobic bottle and one FAN anaerobic bottle. *J Clin Microbiol* 2003;41:213-7.
56. Paisley JW, Lauer BA. Pediatric blood cultures. *Clin Lab Med* 1994;14:17-30.
57. Jaffe DM. Occult bacteremia in children. [Review] [100 refs]. *Adv Pediatr Infect Dis* 1994;9:237-60.
58. Bouza E, Burillo A, Munoz P. Catheter-related infections: diagnosis and intravascular treatment. *Clin Microbiol Infect* 2002;8:265-74.
59. Hall KK, Lyman JA. Updated review of blood culture contamination. *Clin Microbiol Rev* 2006;19:788-802.
60. Garcia X, Sabatier C, Ferrer R, Fontanals D, Duarte M, Colomina M, et al. Differential time to positivity of blood cultures: a valid method for diagnosing catheter-related bloodstream infections in the intensive care unit. *Med Intensiva* 2012;36:169-76.
61. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2009;49:1-45.
62. O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, et al. Guidelines for the prevention of intravascular catheter-related infections. *Am J Infect Control* 2011;39:S1-34.
63. Kaasch AJ, Rieg S, Hellmich M, Kern WV, Seifert H. Differential time to positivity is not predictive for central line-related *Staphylococcus aureus* bloodstream infection in routine clinical care. *J Infect* 2014;68:58-61.
64. Guembe M, Rodriguez-Creixems M, Sanchez-Carrillo C, Martin-Rabadan P, Bouza E. Differential time to positivity (DTTP) for the diagnosis of catheter-related bloodstream infection: do we need to obtain one or more peripheral vein blood cultures? *Eur J Clin Microbiol Infect Dis* 2012;31:1367-72.
65. Beekmann SE, Diekema DJ, Huskins WC, Herwaldt L, Boyce JM, Sherertz RJ, et al. Diagnosing and reporting of central line-associated bloodstream infections. *Infect Control Hosp Epidemiol* 2012;33:875-82.
66. Janakiraman V. Listeriosis in pregnancy: diagnosis, treatment, and prevention. *Rev Obstet Gynecol* 2008;1:179-85.
67. Mylonakis E, Paliou M, Hohmann EL, Calderwood SB, Wing EJ. Listeriosis during pregnancy: a case series and review of 222 cases. *Medicine (Baltimore)* 2002;81:260-9.
68. Fitzsimmons K, Bamber AI, Smalley HB. Infective endocarditis: changing aetiology of disease. *Br J Biomed Sci* 2010;67:35-41.
69. Moreillon P, Que YA. Infective endocarditis. *Lancet* 2004;363:139-49.
70. Fefer P, Raveh D, Rudensky B, Schlesinger Y, Yinnon AM. Changing epidemiology of infective endocarditis: a retrospective survey of 108 cases, 1990-1999. *Eur J Clin Microbiol Infect Dis* 2002;21:432-7.
71. Brouqui P, Raoult D. Endocarditis due to rare and fastidious bacteria. *Clin Microbiol Rev* 2001;14:177-207.
72. McDonald JR. Acute Infective Endocarditis. *Infect Dis Clin North Am* 2009;23:643-64.

## Investigation of Blood Cultures (for Organisms other than *Mycobacterium* species)

73. Kohler W. The present state of species within the genera *Streptococcus* and *Enterococcus*. *Int J Med Microbiol* 2007;297:133-50.
74. Hogevik H, Alestig K. Fungal endocarditis--a report on seven cases and a brief review. *Infection* 1996;24:17-21.
75. Tacke D, Koehler P, Cornely OA. Fungal endocarditis. *Curr Opin Infect Dis* 2013;26:501-7.
76. Petti CA, Bhally HS, Weinstein MP, Joho K, Wakefield T, Reller LB, et al. Utility of extended blood culture incubation for isolation of *Haemophilus*, *Actinobacillus*, *Cardiobacterium*, *Eikenella*, and *Kingella* organisms: a retrospective multicenter evaluation. *J Clin Microbiol* 2006;44:257-9.
77. Baron EJ, Scott JD, Tompkins LS. Prolonged incubation and extensive subculturing do not increase recovery of clinically significant microorganisms from standard automated blood cultures. *Clin Infect Dis* 2005;41:1677-80.
78. Petti CA, Zaidi AK, Mirrett S, Reller LB. Comparison of Isolator 1.5 and BACTEC NR660 aerobic 6A blood culture systems for detection of fungemia in children. *J Clin Microbiol* 1996;34:1877-9.
79. Holliman R. The immunocompromised patient: infection in cancer and transplantation. *Medicine* 2009;37:522-4.
80. Varani S, Stanzani M, Paolucci M, Melchionda F, Castellani G, Nardi L, et al. Diagnosis of bloodstream infections in immunocompromised patients by real-time PCR. *J Infect* 2009;58:346-51.
81. Algar V, Novelli V. Infections in the immunocompromised host. *Paediatr Child Health* 2007;17:132-6.
82. Beebe JL, Koneman EW. Recovery of uncommon bacteria from blood: association with neoplastic disease. *Clin Microbiol Rev* 1995;8:336-56.
83. Kauffman CA. Diagnosis of histoplasmosis in immunosuppressed patients. *Curr Opin Infect Dis* 2008;21:421-5.
84. Lobmaier IV, Vege A, Gaustad P, Rognum TO. Bacteriological investigation--significance of time lapse after death. *Eur J Clin Microbiol Infect Dis* 2009;28:1191-8.
85. Silver H, Sonnenwirth AC. A practical and efficacious method for obtaining significant postmortem blood cultures. *Am J Clin Pathol* 1969;52:433-7.
86. Pryce JW, Roberts SE, Weber MA, Klein NJ, Ashworth MT, Sebire NJ. Microbiological findings in sudden unexpected death in infancy: comparison of immediate postmortem sampling in casualty departments and at autopsy. *J Clin Pathol* 2011;64:421-5.
87. Wilson SJ, Wilson ML, Reller LB. Diagnostic utility of postmortem blood cultures. *Arch Pathol Lab Med* 1993;117:986-8.
88. Scottish Government. Public Health (Scotland) Act. 2008 (as amended).
89. Scottish Government. Public Health etc. (Scotland) Act 2008. Implementation of Part 2: Notifiable Diseases, Organisms and Health Risk States. 2009.
90. The Welsh Assembly Government. Health Protection Legislation (Wales) Guidance. 2010.
91. Home Office. Public Health Act (Northern Ireland) 1967 Chapter 36. 1967 (as amended).
92. Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-

## Investigation of Blood Cultures (for Organisms other than *Mycobacterium* species)

- resistant Enterobacteriaceae, and multidrug-resistant *Pseudomonas aeruginosa*. *Mayo Clin Proc* 2011;86:250-9.
93. Ammerlaan HS, Harbarth S, Buiting AG, Crook DW, Fitzpatrick F, Hanberger H, et al. Secular trends in nosocomial bloodstream infections: antibiotic-resistant bacteria increase the total burden of infection. *Clin Infect Dis* 2013;56:798-805.
  94. Huttunen R, Syrjanen J, Vuento R, Aittoniemi J. Current concepts in the diagnosis of blood stream infections. Are novel molecular methods useful in clinical practice? *Int J Infect Dis* 2013;17:e934-e938.
  95. Rodriguez-Bano J, Navarro MD, Romero L, Muniain MA, de Cueto M, Rios MJ, et al. Bacteremia due to extended-spectrum beta -lactamase-producing *Escherichia coli* in the CTX-M era: a new clinical challenge. *Clin Infect Dis* 2006;43:1407-14.
  96. Worth LJ, Slavin MA. Bloodstream infections in haematology: Risks and new challenges for prevention. *Blood Rev* 2009;23:113-22.
  97. Vigano EF, Vasconi E, Agrappi C, Clerici P. Use of simulated blood cultures for time to detection comparison between BacT/ALERT and BACTEC 9240 blood culture systems. *Diagn Microbiol Infect Dis* 2002;44:235-40.
  98. Rohner P, Pepey B, Auckenthaler R. Comparison of BacT/Alert with Signal blood culture system. *J Clin Microbiol* 1995;33:313-7.
  99. Wilson ML, Mirrett S, McDonald LC, Weinstein MP, Fune J, Reller LB. Controlled clinical comparison of bioMerieux VITAL and BACTEC NR-660 blood culture systems for detection of bacteremia and fungemia in adults. *J Clin Microbiol* 1999;37:1709-13.
  100. Spanjaard L, Kuijper EJ, Dankert J. Clinical comparison of two commercial blood culture systems. *Eur J Clin Microbiol Infect Dis* 2000;19:881-5.
  101. Krisher KK, Gibb P, Corbett S, Church D. Comparison of the BacT/Alert PF pediatric FAN blood culture bottle with the standard pediatric blood culture bottle, the Pedi-BacT. *J Clin Microbiol* 2001;39:2880-3.
  102. McDonald LC, Fune J, Gaido LB, Weinstein MP, Reimer LG, Flynn TM, et al. Clinical importance of increased sensitivity of BacT/Alert FAN aerobic and anaerobic blood culture bottles. *J Clin Microbiol* 1996;34:2180-4.
  103. Department of Health. Taking blood cultures. 2011.
  104. Stohl S, Benenson S, Svirj S, Avidan A, Block C, Sprung CL, et al. Blood cultures at central line insertion in the intensive care unit: comparison with peripheral venipuncture. *J Clin Microbiol* 2011;49:2398-403.
  105. Dwivedi S, Bhalla R, Hoover DR, Weinstein MP. Discarding the initial aliquot of blood does not reduce contamination rates in intravenous-catheter-drawn blood cultures. *J Clin Microbiol* 2009;47:2950-1.
  106. Byard RW. Arterial blood cultures in disseminated fungal disease. *Pediatr Infect Dis J* 1989;8:728-9.
  107. Krumholz HM, Cummings S, York M. Blood culture phlebotomy: switching needles does not prevent contamination. *Ann Intern Med* 1990;113:290-2.
  108. Leisure MK, Moore DM, Schwartzman JD, Hayden GF, Donowitz LG. Changing the needle when inoculating blood cultures. A no-benefit and high-risk procedure. *JAMA* 1990;264:2111-2.

## Investigation of Blood Cultures (for Organisms other than *Mycobacterium* species)

109. Spitalnic SJ, Woolard RH, Mermel LA. The significance of changing needles when inoculating blood cultures: a meta-analysis. *Clin Infect Dis* 1995;21:1103-6.
110. Washington JA, Ilstrup DM. Blood cultures: issues and controversies. *Rev Infect Dis* 1986;8:792-802.
111. Li J, Plorde JJ, Carlson LG. Effects of volume and periodicity on blood cultures. *J Clin Microbiol* 1994;32:2829-31.
112. Connell TG, Rele M, Cowley D, BATTERY JP, Curtis N. How reliable is a negative blood culture result? Volume of blood submitted for culture in routine practice in a children's hospital. *Pediatrics* 2007;119:891-6.
113. Mermel LA, Maki DG. Detection of bacteremia in adults: consequences of culturing an inadequate volume of blood. *Ann Intern Med* 1993;119:270-2.
114. Patel R, Vetter EA, Harmsen WS, Schleck CD, Fadel HJ, Cockerill FR, III. Optimized pathogen detection with 30- compared to 20-milliliter blood culture draws. *J Clin Microbiol* 2011;49:4047-51.
115. Kaditis AG, O'Marcaigh AS, Rhodes KH, Weaver AL, Henry NK. Yield of positive blood cultures in pediatric oncology patients by a new method of blood culture collection. *Pediatr Infect Dis J* 1996;15:615-20.
116. Gonsalves WI, Cornish N, Moore M, Chen A, Varman M. Effects of volume and site of blood draw on blood culture results. *J Clin Microbiol* 2009;47:3482-5.
117. Kellogg JA, Manzella JP, Bankert DA. Frequency of low-level bacteremia in children from birth to fifteen years of age. *J Clin Microbiol* 2000;38:2181-5.
118. Mirrett S, Reller LB, Petti CA, Woods CW, Vazirani B, Sivadas R, et al. Controlled clinical comparison of BacT/ALERT standard aerobic medium with BACTEC standard aerobic medium for culturing blood. *J Clin Microbiol* 2003;41:2391-4.
119. Roh KH, Kim JY, Kim HN, Lee HJ, Sohn JW, Kim MJ, et al. Evaluation of BACTEC Plus aerobic and anaerobic blood culture bottles and BacT/Alert FAN aerobic and anaerobic blood culture bottles for the detection of bacteremia in ICU patients. *Diagn Microbiol Infect Dis* 2012;73:239-42.
120. Flayhart D, Borek AP, Wakefield T, Dick J, Carroll KC. Comparison of BACTEC PLUS blood culture media to BacT/Alert FA blood culture media for detection of bacterial pathogens in samples containing therapeutic levels of antibiotics. *J Clin Microbiol* 2007;45:816-21.
121. Miller NS, Rogan D, Orr BL, Whitney D. Comparison of BD Bactec Plus blood culture media to VersaTREK Redox blood culture media for detection of bacterial pathogens in simulated adult blood cultures containing therapeutic concentrations of antibiotics. *J Clin Microbiol* 2011;49:1624-7.
122. Ziegler R, Johnscher I, Martus P, Lenhardt D, Just HM. Controlled clinical laboratory comparison of two supplemented aerobic and anaerobic media used in automated blood culture systems to detect bloodstream infections. *J Clin Microbiol* 1998;36:657-61.
123. Wilson ML, Mirrett S, Meredith FT, Weinstein MP, Scotto V, Reller LB. Controlled clinical comparison of BACTEC plus anaerobic/F to standard anaerobic/F as the anaerobic companion bottle to plus aerobic/F medium for culturing blood from adults. *J Clin Microbiol* 2001;39:983-9.
124. Knepper JG, Anthony BF. Diminished growth of *Pseudomonas aeruginosa* in unvented blood-culture bottles. *Lancet* 1973;2:285-7.
125. Gantz NM, Medeiros AA, Swain JL, O'Brien TF. Vacuum blood-culture bottles inhibiting growth of *Candida* and fostering growth of *Bacteroides*. *Lancet* 1974;2:1174-6.

## Investigation of Blood Cultures (for Organisms other than *Mycobacterium* species)

126. Mirrett S, Everts RJ, Reller LB. Controlled comparison of original vented aerobic fan medium with new nonvented BacT/ALERT FA medium for culturing blood. *J Clin Microbiol* 2001;39:2098-101.
127. Waites KB, Canupp KC. Evaluation of BacT/ALERT system for detection of *Mycoplasma hominis* in simulated blood cultures. *J Clin Microbiol* 2001;39:4328-31.
128. Eng J, Holten E. Gelatin neutralization of the inhibitory effect of sodium polyanethol sulfonate on *Neisseria meningitidis* in blood culture media. *J Clin Microbiol* 1977;6:1-3.
129. Davies S, Eggington R. Recovery of *Mycoplasma hominis* from blood culture media. *Med Lab Sci* 1991;48:110-3.
130. Courcol RJ, Durocher AV, Roussel-Delvallez M, Fruchart A, Martin GR. Routine evaluation of BACTEC NR-16A and NR-17A media. *J Clin Microbiol* 1988;26:1619-22.
131. Smith SM, Eng RH. Effectiveness of antibiotic removal by the antibiotic-binding blood culture systems. *Diagn Microbiol Infect Dis* 1985;3:201-12.
132. Wright AJ, Thompson RL, McLimans CA, Wilson WR, Washington JA. The antimicrobial removal device. A microbiological and clinical evaluation. *Am J Clin Pathol* 1982;78:173-7.
133. Jessamine PG, Hoban DJ, Forward KR. Positive Bactec resin cultures do not influence antimicrobial selection. *Diagn Microbiol Infect Dis* 1990;13:281-4.
134. Kirn TJ, Weinstein MP. Update on blood cultures: how to obtain, process, report, and interpret. *Clin Microbiol Infect* 2013;19:513-20.
135. Washington JA. Collection, transport, and processing of blood cultures. *Clin Lab Med* 1994;14:59-68.
136. Hawkins BL, Peterson EM, de la Maza LM. Improvement of positive blood culture detection by agitation. *Diagn Microbiol Infect Dis* 1986;5:207-13.
137. Prag J, Nir M, Jensen J, Arpi M. Should aerobic blood cultures be shaken intermittently or continuously? *APMIS* 1991;99:1078-82.
138. Yagupsky P, Peled N, Press J, Abramson O, Abu-Rashid M. Comparison of BACTEC 9240 Peds Plus medium and isolator 1.5 microbial tube for detection of *Brucella melitensis* from blood cultures. *J Clin Microbiol* 1997;35:1382-4.
139. Herne V, Nelovkov A, Kutt M, Ivanova M. Diagnostic performance and therapeutic impact of LightCycler SeptiFast assay in patients with suspected sepsis. *Eur J Microbiol Immunol (Bp)* 2013;3:68-76.
140. Sullivan KV, Turner NN, Roundtree SS, McGowan KL. Rapid detection of methicillin-resistant *Staphylococcus aureus* (MRSA) and methicillin-susceptible *Staphylococcus aureus* (MSSA) using the KeyPath MRSA/MSSA blood culture test and the BacT/ALERT system in a pediatric population. *Arch Pathol Lab Med* 2013;137:1103-5.
141. Buchan BW, Ginocchio CC, Manii R, Cavagnolo R, Pancholi P, Swyers L, et al. Multiplex identification of gram-positive bacteria and resistance determinants directly from positive blood culture broths: evaluation of an automated microarray-based nucleic acid test. *PLoS Med* 2013;10:e1001478.
142. Martiny D, Debaugnies F, Gateff D, Gerard M, Aoun M, Martin C, et al. Impact of rapid microbial identification directly from positive blood cultures using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry on patient management. *Clin Microbiol Infect* 2013;19:E568-E581.

## Investigation of Blood Cultures (for Organisms other than *Mycobacterium* species)

143. Yossepowitch O, Dan M, Kutchinsky A, Gottesman T, Schwartz-Harari O. A cost-saving algorithm for rapid diagnosis of *Staphylococcus aureus* and susceptibility to oxacillin directly from positive blood culture bottles by combined testing with BinaxNOW(R) *S. aureus* and Xpert MRSA/SA assay. *Diagn Microbiol Infect Dis* 2014.
144. Lagace-Wiens PR, Alfa MJ, Manickam K, Karlowsky JA. Thermostable DNase is superior to tube coagulase for direct detection of *Staphylococcus aureus* in positive blood cultures. *J Clin Microbiol* 2007;45:3478-9.
145. Qian Q, Eichelberger K, Kirby JE. Rapid identification of *Staphylococcus aureus* in blood cultures by use of the direct tube coagulase test. *J Clin Microbiol* 2007;45:2267-9.
146. Myrick BA, Ellner PD. Evaluation of the latex slide agglutination test for identification of *Staphylococcus aureus*. *J Clin Microbiol* 1982;15:275-7.
147. Davies S, Gear JE, Mason CM, McIntyre SM, Hall L. Streptococcus grouping latex kits: evaluation of five commercially available examples. *Br J Biomed Sci* 2003;60:136-40.
148. McDonald CL, Chapin K. Rapid identification of *Staphylococcus aureus* from blood culture bottles by a classic 2-hour tube coagulase test. *J Clin Microbiol* 1995;33:50-2.
149. Enoch DA, Cooke FJ, Guha S, Brown NM. Thermostable nuclease: a study of clinical impact. *J Antimicrob Chemother* 2008;61:754-5.
150. Speers DJ, Olma TR, Gilbert GL. Evaluation of four methods for rapid identification of *Staphylococcus aureus* from blood cultures. *J Clin Microbiol* 1998;36:1032-4.
151. Jin WY, Jang SJ, Lee MJ, Park G, Kim MJ, Kook JK, et al. Evaluation of VITEK 2, MicroScan, and Phoenix for identification of clinical isolates and reference strains. *Diagn Microbiol Infect Dis* 2011;70:442-7.
152. Mittman SA, Huard RC, Della-Latta P, Whittier S. Comparison of BD Phoenix to Vitek 2, Microscan MICroSTREP, and Etest for antimicrobial susceptibility testing of *Streptococcus pneumoniae*. *J Clin Microbiol* 2009;47:3557-61.
153. Carrara L, Navarro F, Turbau M, Seres M, Moran I, Quintana I, et al. Molecular diagnosis of bloodstream infections with a new dual priming oligonucleotide-based multiplex PCR assay. *J Med Microbiol* 2013.
154. Lyle N, Boyd J. The potential for PCR based testing to improve diagnosis and treatment of sepsis. *Curr Infect Dis Rep* 2013;15:372-9.
155. Carbonnelle E, Mesquita C, Bille E, Day N, Dauphin B, Beretti JL, et al. MALDI-TOF mass spectrometry tools for bacterial identification in clinical microbiology laboratory. *Clin Biochem* 2011;44:104-9.
156. Klein S, Zimmermann S, Kohler C, Mischnik A, Alle W, Bode KA. Integration of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in blood culture diagnostics: a fast and effective approach. *J Med Microbiol* 2012;61:323-31.
157. Wuppenhorst N, Consoir C, Lorch D, Schneider C. Direct identification of bacteria from charcoal-containing blood culture bottles using matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry. *Eur J Clin Microbiol Infect Dis* 2012.
158. Dekker JP, Branda JA. MALDI-TOF mass spectrometry in the clinical microbiology laboratory. *Clinical Microbiology Newsletter* 2011;33:87-93.



## Investigation of Blood Cultures (for Organisms other than *Mycobacterium* species)

159. Schmidt V, Jarosch A, Marz P, Sander C, Vacata V, Kalka-Moll W. Rapid identification of bacteria in positive blood culture by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. *Eur J Clin Microbiol Infect Dis* 2012;31:311-7.
160. British Society for Antimicrobial Chemotherapy. BSAC Methods for Antimicrobial Susceptibility Testing. 2013.
161. Coyle MB, McGonagle LA, Plorde JJ, Clausen CR, Schoenknecht FD. Rapid antimicrobial susceptibility testing of isolates from blood cultures by direct inoculation and early reading of disk diffusion tests. *J Clin Microbiol* 1984;20:473-7.
162. Mushtaq S, Warner M, Cloke J, Afzal-Shah M, Livermore DM. Performance of the Oxoid M.I.C.Evaluator Strips compared with the Etest assay and BSAC agar dilution. *J Antimicrob Chemother* 2010;65:1702-11.
163. NHS Quality Improvement Scotland. Blood Culture: Driver Diagram, Implementation Framework, Priority Elements Checklist, Data Measurement Tool and Measurement Plan Working Draft. 2011.
164. Harvey DJ, Albert S. Standardized definition of contamination and evidence-based target necessary for high-quality blood culture contamination rate audit. *J Hosp Infect* 2013;83:265-6.
165. Freeman JT, Chen LF, Sexton DJ, Anderson DJ. Blood culture contamination with Enterococci and skin organisms: implications for surveillance definitions of primary bloodstream infections. *Am J Infect Control* 2011;39:436-8.
166. Roth A, Wiklund AE, Palsson AS, Melander EZ, Wullt M, Cronqvist J, et al. Reducing blood culture contamination by a simple informational intervention. *J Clin Microbiol* 2010;48:4552-8.
167. European Parliament. UK Standards for Microbiology Investigations (SMIs) use the term "CE marked leak proof container" to describe containers bearing the CE marking used for the collection and transport of clinical specimens. The requirements for specimen containers are given in the EU *in vitro* Diagnostic Medical Devices Directive (98/79/EC Annex 1 B 2.1) which states: "The design must allow easy handling and, where necessary, reduce as far as possible contamination of, and leakage from, the device during use and, in the case of specimen receptacles, the risk of contamination of the specimen. The manufacturing processes must be appropriate for these purposes".
168. Official Journal of the European Communities. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on *in vitro* diagnostic medical devices. 7-12-1998. p. 1-37.
169. Klaerner HG, Eschenbach U, Kamereck K, Lehn N, Wagner H, Miethke T. Failure of an automated blood culture system to detect nonfermentative gram-negative bacteria. *J Clin Microbiol* 2000;38:1036-41.
170. Seegmuller I, Eschenbach U, Kamereck K, Miethke T. Sensitivity of the BacT/ALERT FA-medium for detection of *Pseudomonas aeruginosa* in pre-incubated blood cultures and its temperature-dependence. *J Med Microbiol* 2004;53:869-74.
171. Narasimhan SL, Weinstein AJ. Infective endocarditis due to a nutritionally deficient streptococcus. *J Pediatr* 1980;96:61-2.
172. McCarthy LR, Bottone EJ. Bacteremia and endocarditis caused by satelliting streptococci. *Am J Clin Pathol* 1974;61:585-91.
173. Casetta A, Derouin V, Boussougant Y. Absence of spontaneous autolysis of *Streptococcus pneumoniae* in aerobic fan culture bottles in a commercial blood culture system. *Eur J Clin Microbiol Infect Dis* 1996;15:616-7.

## Investigation of Blood Cultures (for Organisms other than *Mycobacterium* species)

174. Davis JC. A gram stain for smears of blood cultures, body fluids and tissues. *Am J Med Technol* 1976;42:417-23.
175. Health and Safety Executive. Safe use of pneumatic air tube transport systems for pathology specimens. 9/99.
176. Department for transport. Transport of Infectious Substances, 2011 Revision 5. 2011.
177. World Health Organization. Guidance on regulations for the Transport of Infectious Substances 2013-2014. 2012.
178. Home Office. Anti-terrorism, Crime and Security Act. 2001 (as amended).
179. Advisory Committee on Dangerous Pathogens. The Approved List of Biological Agents. Health and Safety Executive. 2013. p. 1-32
180. Advisory Committee on Dangerous Pathogens. Infections at work: Controlling the risks. Her Majesty's Stationery Office. 2003.
181. Advisory Committee on Dangerous Pathogens. Biological agents: Managing the risks in laboratories and healthcare premises. Health and Safety Executive. 2005.
182. Advisory Committee on Dangerous Pathogens. Biological Agents: Managing the Risks in Laboratories and Healthcare Premises. Appendix 1.2 Transport of Infectious Substances - Revision. Health and Safety Executive. 2008.
183. Centers for Disease Control and Prevention. Guidelines for Safe Work Practices in Human and Animal Medical Diagnostic Laboratories. *MMWR Surveill Summ* 2012;61:1-102.
184. Health and Safety Executive. Control of Substances Hazardous to Health Regulations. The Control of Substances Hazardous to Health Regulations 2002. 5th ed. HSE Books; 2002.
185. Health and Safety Executive. Five Steps to Risk Assessment: A Step by Step Guide to a Safer and Healthier Workplace. HSE Books. 2002.
186. Health and Safety Executive. A Guide to Risk Assessment Requirements: Common Provisions in Health and Safety Law. HSE Books. 2002.
187. Health Services Advisory Committee. Safe Working and the Prevention of Infection in Clinical Laboratories and Similar Facilities. HSE Books. 2003.
188. British Standards Institution (BSI). BS EN12469 - Biotechnology - performance criteria for microbiological safety cabinets. 2000.
189. British Standards Institution (BSI). BS 5726:2005 - Microbiological safety cabinets. Information to be supplied by the purchaser and to the vendor and to the installer, and siting and use of cabinets. Recommendations and guidance. 24-3-2005. p. 1-14
190. Baron EJ, Miller JM, Weinstein MP, Richter SS, Gilligan PH, Thomson RB, Jr., et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2013 Recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). *Clin Infect Dis* 2013;57:e22-e121.
191. Kelly MT, Roberts FJ, Henry D, Geere I, Smith JA. Clinical comparison of isolator and BACTEC 660 resin media for blood culture. *J Clin Microbiol* 1990;28:1925-7.
192. Bosshard PP. Incubation of fungal cultures: how long is long enough? *Mycoses* 2011;54:e539-e545.

## Investigation of Blood Cultures (for Organisms other than *Mycobacterium* species)

193. Morris AJ, Byrne TC, Madden JF, Reller LB. Duration of incubation of fungal cultures. J Clin Microbiol 1996;34:1583-5.
194. Bhatti S, Vilenski L, Tight R, Smego RA, Jr. Histoplasma endocarditis: clinical and mycologic features and outcomes. J Infect 2005;51:2-9.
195. Public Health England. Laboratory Reporting to Public Health England: A Guide for Diagnostic Laboratories. 2013. p. 1-37.
196. Department of Health. Health Protection Legislation (England) Guidance. 2010. p. 1-112.
197. Lai CC, Wang CY, Liu WL, Huang YT, Liao CH, Hsueh PR. Time to positivity in blood cultures of staphylococci: clinical significance in bacteremia. J Infect 2011;62:249-51.